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UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA
th se
THE FEDERAL TRADE COMMISSION,
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Plaintiff,
Civ. No. 1.-98-CV-3114 (TFH)

v.
MYLAN LABORATORIES, INC.,
CAMBREX CORP.,
PROFARMACO S.R.L., and
GYMA LABORATORIES OF AMERICA, INC.,
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THE STATE OF CONNECTICUT, et al.
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Plaintiffs,
v.

"Tl

33'

C 23

Civ. No. L98-CV-3115 (TFH)

MYLAN LABORATORIES, INC.,
CAMBREX CORP.,
PROFARMACO S.R.L.,
GYMA LABORATORIES OF AMERICA, INC.,
and SST CORP.,
Defendants.

NOTICE OF SETTLEMENT AND FILING OF
SETTLEMENT AGREEMENTS
Plaintiff State o f Ohio, as liaison counsel for Plaintiff States, and on behalf o f
Plaintiff Federal Trade Commission and Defendants My lan Laboratories, Inc., Cambrex
Corp., Profarmaco S.r.l., Gyma Laboratories o f America, Inc., and SST Corp., hereby
provides notice to this Court that all parties in the above-captioned actions have entered

into settlement agreements, which are filed herewith.

Respectfully Submitted,
Betty D. Montgomery
Attorney General of Ohio

/

iClitchell L. Gémile, Esq.
Principal Attorney
Office o f the Ohio Attorney General
Antitrust Section
140 E. Town St., 12th Floor
Columbus, Ohio 43215
Phone: (614) 466-4328

CERTIFICATE OF SERVICE
I hereby certify that a true and correct copy of the Notice o f Settlement and Filing
o f Settlement Agreements was sent by ordinary U.S. mail the first day o f February 2001
to:

Richard A. Feinstein
Melvin H. Orlans
Federal Trade Commission
4500 Pennsylvania Avenue, N.W.
Washington, DC 20580

Robert S. Schächter
Joseph Tusa
Zwerling Schächter & Zwerling, LLP
767 Third Avenue
New York, NY 10017

James B. Weidner
James Miller
Clifford Chance Rogers & Wells, LLP
200 Park Avenue
New York, NY 10166

Sidney S. Rosdeitcher
Robert Kravitz
Paul, Weiss, Rifkind Wharton &
Garrison
1285 Avenue o f the Americas
New York, NY 10019

Joseph Simons
Clifford Chance Rogers & Wells, LLP
607 Fourteenth Street, N.W.
Washington, DC 20005-2018
Thomas Campbell
John T. Cusack
Gardner, Carton & Douglas
321 North Clark Street, Suite 3000
Chicago, IL 60610-4795
Stanley Grossman
Linda P. Nussbaum
Pomerantz, Haudek, Block, Grossman &
Gross LLP
100 Park Avenue
New York, NY 10017
Bernard Persky
Goodkind Labaton Rudoff & Sucharow, LLP
100 Park Avenue
New York, NY 10017

Notice of Settlement

F. Barron Grier, III
Grier Law Firm, LLC
810 Dutch Square Boulevard, Suite 103
Columbia, South Carolina 29210
Gary W. Kubek
Christopher K. Tahbaz
Debevoise & Plimpton
875 Third Avenue
New York, NY 10022
Irving Scher
Weil, Gotshal & Manges, LLP
767 Fifth Avenue
New York, NY 10153
David Hickerson
Weil, Gotshal & Manges, LLP
1615 L Street, N.W.
Suite 700
Washington, D.C. 20036

SETTLEMENT AGREEMENT BETWEEN PLAINTIFF STATES, THE FEDERAL
TRADE COMMISSION AND MYLAN LABORATORIES, INC.. GYMA
LABORATORIES OF AMERICA. INC., PROFARMACQ S.R.L.. CAMBREX CORP.
This Settlement Agreement is made and entered into this 30th day o f January, 2001, by and
between the States and Commonwealths o f Alabama, Alaska, Arizona, Arkansas, California,
Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas,
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,
Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina,
South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin,
and Wyoming, through their respective Attorneys General, and the District o f Columbia, through
its Corporation Counsel, plus any other state that has elected or elects to join in the terms o f the
Settlement Agreement, through their respective Attorneys (“Plaintiff States” as defined below), the
Federal Trade Commission (“Commission”), and Mylan Laboratories, Inc., Gyma Laboratories o f
America, Inc., Profarmaco S.r.l. and Cambrex Corp., through their undersigned counsel,
(collectively, the “Parties”). Any state electing to join in the terms o f the Settlement Agreement shall
do so by executing a signature page which shall be appended to this Agreement.
WHEREAS, the Litigating Plaintiff States (as defined in Section I.N below) on December
21, 1998, as amended on February 8, 1999, and again on May 13, 1999, filed suit against Settling
Defendants and SST Corporation in the United States District Court for the District o f Columbia on
their own behalf, on behalf o f state agencies, and through their equitable or common law authority
or as representative of or parens patriae on behalf of natural person citizens of those states, alleging
monopolization, attempted monopolization, and agreements in restraint o f trade, in violation of
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federal and state antitrust and unfair competition or consumer protection laws, and seeking injunctive
relief, civil penalties, damages, divestment, disgorgement, restitution and other equitable relief;
WHEREAS, a Third Amended Complaint will be filed contemporaneously with this
Settlement Agreement by the Plaintiff States in the United States District Court for the District of
Columbia adding those states which have chosen to opt into this Settlement Agreement;
WHEREAS, the Commission on December 21,1998, as amended on February 8,1999, filed
its Complaint against Settling Defendants in the United States District Court for the District of
Columbia seeking permanent injunctive and other equitable relief, including disgorgement, and
alleging that Settling Defendants monopolized, attempted to monopolize, conspired to monopolize
and entered into agreements that unreasonably restrained trade in the markets for lorazepam and
clorazepate active pharmaceutical ingredients and tablets;
WHEREAS, the Parties have engaged in extensive analysis o f the pertinent facts. The
Litigating Plaintiff States and the Commission have conducted an extensive investigation relating
to the claims and underlying events and transactions alleged in the Commission’s Complaint and the
Plaintiff States’ Complaint, as well as extensive legal research. As a result, the Litigating Plaintiff
States and the Commission are thoroughly familiar with the liability and damages aspects o f the
claims they have asserted in the Commission’s Complaint and the Plaintiff States’ Complaint;
WHEREAS, over the course o f the Parties’ extensive arm’s-length negotiations, the
Litigating Plaintiff States have concluded that the proposed settlement embodied in this Settlement
Agreement is fair, adequate and reasonable. Among the factors considered in that determination are
the sharply contested legal and factual issues involved in these actions and the risks and costs
attendant upon further prosecution o f these actions;
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WHEREAS, Settling Defendants, likewise recognizing the many sharply contested legal and
factual issues involved and the risks and costs attendant upon further litigation of the claims in these
actions, and while continuing to deny vigorously the allegations, any violation of law or wrongdoing,
and any liability with respect to any and all claims asserted in the Commission’s Complaint and in
the Plaintiff States’ Complaint, have concluded that it is desirable that all o f the claims in these
actions which have, or could have, been asserted against Settling Defendants be compromised and
settled;
WHEREAS, the Parties have each determined it to be in their respective best interests to
resolve this dispute and enter into this Settlement Agreement;
NOW, THEREFORE, WITNESSETH:
L DEFINITIONS
As used herein:
A.

“Agency Account” means a separate account, to be established within the State Fund,

funded pursuant to Section IV. A. below. The Agency Account shall be distributed as specified in the
Government Compensation Plan.
B.

“Class” means the members o f a class to be certified for settlement purposes only

pursuant to this Settlement Agreement and Rule 23 o f the Federal Rules o f Civil Procedure, which
shall include all natural person consumers within Plaintiff States where such a class action may be
brought, not otherwise represented by the Plaintiff States as parens patriae, who purchased either
or both o f the Relevant Dnigs during the Relevant Period.
C.

“Commission” means the Federal Trade Commission.
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D.

“Commission's Complaint” means the complaint filed by the Commission on

December 21, 1998, as amended on February 8, 1999, against Settling Defendants in the United
States District Court for the District o f Columbia.
E.

“Consumer Distribution Plan” means the plan or method o f allocation o f the

Consumer Fund, which shall be submitted to the Court for approval, and which is consistent with
the Guidelines Governing Development o f Consumer Distribution Plan, included as Attachment 7.
F.

“Consumer Fund” means an interest-bearing escrow account, established pursuant to

the Escrow Agreement and administered by the Escrow Agent. The principal o f the Consumer Fund
shall be funded as set forth in section IV.A. below. The Consumer Fund shall be distributed as
specified in the Consumer Distribution Plan
G.

“ Cost and Fee Account” means a segregated account to be established within the

State Fund, to be funded as set forth in Section IV.B.
H.

“Court” means the United States District Court for the District o f Columbia.

I.

“Effective Date” means the date on which this Settlement Agreement becomes

effective. The Effective Date shall occur when all o f the following conditions have been satisfied,
unless one or more o f such conditions is modified in a writing signed by the Parties:
1.

Execution o f this Settlement Agreement;

2.

Entry by the Court o f the Stipulated Permanent Injunction;

3.

Entry by the Court o f a Preliminary Approval Order substantially in

conformance with the terms o f this Settlement Agreement;
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4.

Expiration of the period within which consumers represented parens patriae

and members o f the proposed Class must exercise their rights to be excluded from parens patriae
representation or from the Class;
5.

Final approval by the Court of the Settlement embodied herein;

6.

Entry by the Court o f the Final Judgment and Order substantially in

conformity with the terms o f this Settlement Agreement;
7.

The Final Judgment and Order shall become final, which shall be deemed to

occur upon the expiration of the tenth day after the applicable time for appeals of the Finai Judgment
and Order (whether as o f right or upon showing o f excusable neglect or good cause) without any
appeal having been taken, or, if an appeal is taken, upon the expiration of the tenth day after the
Final Judgment and Order is affirmed by the appellate court with no possibility of subsequent appeal
or judicial review thereof. For purposes o f this Subsection, an “appeal" shall include any Petition
for a Writ of Certiorari that may be filed in connection with the approval or disapproval o f this
Settlement Agreement; and
8.

As of the time the conditions contained in Subsections I.I.l. through I.I.7.

above are satisfied, the right to terminate and withdraw from this Settlement Agreement granted
pursuant to Section X below shall not have been exercised by any o f the Parties.
J.

“Escrow Agent” means the person or entity chosen by the Plaintiff States and

designated pursuant to the Escrow Agreement to administer the Consumer Fund and State Fund
pursuant to the terms o f this Settlement Agreement.
K.

“Escrow Agreement” means the escrow agreement, substantially in the form o f

Attachment 1 hereto.
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L.

“Final Judgment and Order” means the Court's final, appealable order, substantially

in the form o f Attachment 2 hereto.
M.

“Government Compensation Plan" means the plan or method of allocation o f the

State Fund, which shall be submitted to the Court, and which is consistent with the Guidelines
Governing Development of Government Compensation Plan, included as Attachment 6.
N.

“Litigating Plaintiff States” means the 33 Plaintiff States that participated in the

litigation and negotiation o f the settlement o f these actions: Alaska, Arkansas, California, Colorado,
Connecticut, District o f Columbia, Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine,
Maryland, Michigan, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio,
Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont,
Washington, West Virginia, and Wisconsin.1
O.

“Notice” means the notice or notices o f this Settlement Agreement and hearing

thereof that are to be published and/or mailed to members o f the Settlement Group pursuant to
Section VII.
P.

“Notice Plan” means the Court-approved process by which the Plaintiff States will

effectuate the Notice.
Q.

“Person” means any natural person, partnership, corporation, or business entity.

1For purposes o f the litigation and this settlement, the definition of “Litigating Plaintiff
States” or “Plaintiff States” does not include the University o f California. It is stipulated by the
Parties that the California Attorney General has not represented the interests o f the University o f
California in the litigation or the settlement thereof, and the University o f California has not been
participating in this action.
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R.

“Plaintiff States” means the Litigating Plaintiff States and any State which is or which

becomes a party to this Settlement Agreement, as provided in Section IX. hereof, through the State's
Attorney General, individually and as authorized by law, in the State’s sovereign capacity, on behalf
o f state agencies, in a statutory, equitable and/or common law capacity, and as representative of
and/or parens patriae on behalf o f all natural person citizens o f such state who have purchased either
or both o f the Relevant Drugs during the Relevant Period.
S.

“Plaintiff States’ Complaint" means the complaint filed by the Litigating Plaintiff

States on December 21, 1998, as amended on February 8, 1999 and again on May 13, 1999 and the
Third Amended Complaint filed herewith by the Plaintiff States.
T.

“Preliminary Approval Order” means the Court's order preliminarily approving this

Settlement Agreement and establishing a schedule for Notice and further proceedings, as set forth
in Section VII below, and substantially in the form o f Attachment 3 hereto.
U.

“Released Claims” means all claims, counterclaims, set-offs, demands, actions, rights,

liabilities, and causes of action arising under federal or state antitrust, unfair methods of competition,
or consumer protection laws, under state or federal unfair or deceptive trade practices acts, or under
common law, asserted or that could have been asserted, by the Commission, by Settling Members
o f the Settlement Group, or by the Plaintiff States on behalf o f state agencies and/or natural person
consumers within the Plaintiff States against Settling Defendants arising from the facts, matters,
transactions, events, occurrences, acts, disclosures, statements, omissions, or failures to act set forth
or alleged in the Commission’s Complaint or in the Plaintiff States’ Complaint.
V.

“Relevant Drugs” means generic lorazépam or clorazepate sold in the United States.

W.

“Relevant Period” means the period from January 1, 1998 to December 31, 1999.
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X.

“Settlement Group” means all natural person consumers represented by Attorneys

General for the Plaintiff States, individually and as authorized by law in a statutory, equitable and/or
common law capacity, as parens patriae and/or as representatives o f the Class.
Y.

“Settling Defendants” means Mylan Laboratories, Inc. (“Mylan”), Gyma Laboratories

o f America, Inc. (“Gyma”), Profarmaco S.r.l. (“Profarmaco"), Cambrex Corp., (“Cambrex”) and any
and all o f their affiliates, subsidiaries, divisions and other organizational units o f any kind, their
successors and assigns, and their former, current and future officers, directors, employees, agents,
attorneys, representatives, shareholders, partners and other persons acting on their behalf.
Z.

“Settling Members o f the Settlement Group” means each and every member o f the

Settlement Group who does not exercise his or her right to exclude himself or herself from the
Settlement Group pursuant to a proper written request for exclusion postmarked on or before the date
to be set by the Court.
AA.

“ State Fund” means an interest-bearing escrow account established pursuant to the

Escrow Agreement and administered by the Escrow Agent. The principal of the State Fund shall
be funded as set forth in Sections IV.A. and B. below, and shall be segregated into an Agency
Account and a Cost and Fee Account.
BB.

“State Liaison Counsel” or “Liaison Counsel for Plaintiff States” means the Attorney

General o f the State o f Ohio.
CC.

“Stipulated Permanent Injunction” means the injunction entered into between the

Commission and the Settling Defendants and approved by the Commission on November 29, 2000,
in the action entitled Federal Trade Commission v. Mylan, et al., in the form o f Attachment 4.
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II. AGREEMENT
Subject to the approval o f the Court, the Parties agree to compromise, settle and resolve
fully and finally on the terms set forth herein, all Released Claims.
III. INJUNCTION
As part o f this Settlement Agreement, the Commission and the Settling Defendants have
entered into the Stipulated Permanent Injunction in the form o f Attachment 4, the terms and
conditions o f which are incorporated into this Settlement Agreement as though set forth in this
Section III in full. The term set forth in the Stipulated Permanent Injunction shall govern the term
o f enforcement o f this Section III. The Stipulated Permanent Injunction may be enforced by the
Plaintiff States in the following manner:
A.

Settling Defendants shall provide the notices and/or reports pursuant to Sections VI,

VII and VIII o f the Stipulated Permanent Injunction to State Liaison Counsel, c/o Chief, Antitrust
Section, Office o f the Ohio Attorney General, 140 East Town Street, 12th Floor, Columbus, Ohio
43215.
B.

Communications involving the

Stipulated Permanent Injunction shall be

communicated to Settling Defendants by State Liaison Counsel. All such communications shall be
addressed to Settling Defendants as provided for in Section XI(G) o f this Settlement Agreement.
C.

Each Plaintiff State shall enforce Sections III, IV and V o f the Stipulated Permanent

Injunction through a committee comprised of the Offices o f the Attorneys General for the States of
Ohio, Maryland and Kentucky (the “Committee”).
D.

The Stipulated Permanent Injunction shall be enforced by the Plaintiff States by and

through the Committee in the District Court for the District o f Columbia.
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IV. MONETARY PAYMENT
A.

Mylan Pharmaceuticals, Inc. has agreed to pay $ 100 million in cash in full and final

settlement o f the claims against all Settling Defendants as set forth in the Commission's Complaint
and in the Plaintiff States’ Complaint and in exchange for the release of all Released Claims. This
amount has been paid in two wire transfers, as set forth below, c/o the Escrow Agent appointed
pursuant to Section V of this Agreement. O f the $100 million, $28,217,983.00 has been paid into
the Agency Account o f the State Fund, and the remaining $71,782,017.00 has been paid into the
Consumer Fund.
B.

Mylan Pharmaceuticals, Inc. further agrees to pay the Litigating Plaintiff States up

to $8 million for their attorneys’ fees and costs incurred in the investigation and litigation o f this
matter. This amount shall be paid into the Cost and Fee Account o f the State Fund within five (5)
business days following entry o f the Final Judgment and Order by the Court.
C.

The payments made by Mylan Pharmaceuticals, Inc. pursuant to Sections IV. A. and

IV.B. are not, and shall not, be considered the payment o f a penalty or fine under any state or federal
laws, rules or regulations or any other applicable statute or provision.
D.

Plaintiff States, on behalf of state agencies and Settling Members o f the Settlement

Group, and the Commission agree to release the Released Claims in exchange for the injunctive and
monetary provisions contained in this Settlement Agreement. Upon the Effective Date, Plaintiff
States, Settling Members of the Settlement Group and the Commission shall be deemed to have
released and forever discharged Settling Defendants from all liability for the Released Claims.
E.

Mylan warrants that, as of the date of this Settlement Agreement, neither it nor any

o f its affiliates, including but not limited to Mylan Pharmaceuticals, Inc., is insolvent, nor will any
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payment to the Consumer Fund and State Fund render it or any o f its affiliates, including but not
limited to, Mylan Pharmaceuticals, Inc., insolvent, within the meaning o f and/or for the purposes of
the United States Bankruptcy Code. If a case is commenced with respect to Mylan or any o f its
affiliates, under Title 11 of the United States Code (Bankruptcy), or a trustee, receiver or conservator
is appointed under any similar law, and in the event o f the entry o f a final order of a court of
competent jurisdiction determining the payment of the principal amount o f the Consumer Fund or
State Fund, and any accrued interest, or any portion thereof, by or on behalf of Mylan or any affiliate
o f Mylan, to be a preference, voidable transfer, fraudulent transfer or similar transaction, and if
pursuant to an order o f a court o f competent jurisdiction monies paid by Mylan or any o f its
affiliates, into the Consumer Fund or the State Fund pursuant to this agreement are either not
delivered or are returned to Mylan or any o f its affiliates, or the trustee, receiver, or conservator
appointed by a court in any bankruptcy proceeding with respect to Mylan or any of its affiliates, then
this Settlement Agreement shall be terminated and cancelled as set forth in Section X herein. In the
event that Mylan has funded the Cost and Fee Account prior to any filing under Title 11 o f the
United States Code, this Section IV.E shall apply to the Consumer Fund and the Agency Account
only.
F.

Plaintiff States, Settling Members o f the Settlement Group and the Commission shall

also be deemed to have expressly waived any rights or benefits, if available, under Section 1542 of
the California Civil Code, which provides:
A general release does not extend to claims which the creditor does not know or
suspect to exist in his favor at the time o f executing the release, which if known by
him, must have materially affected his settlement with the debtor.
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Settling Members of the Settlement Group shall be advised o f the statutory language of California
Civil Code Section 1542 in the Notice and, with this understanding, nevertheless shall elect to and
shall assume all risks for claims heretofore and hereafter arising, whether known or unknown, from
the subject of the Released Claims, and specifically waive any rights they may have under California
Civil Code Section 1542. Settling Members of the Settlement Group shall also be fully advised that
if the facts with respect to which the Released Claims are given and the dismissal with prejudice
contained in the Final Judgment and Order are found hereafter to be other than, or different from,
the facts now believed by them to be true, they shall expressly accept and assume the risk o f such
possible differences and facts, and shall agree that the release shall be and remain effective
notwithstanding such differences in facts.
G.

The Parties agree that the decision by the Court regarding the amount to be deposited

into the Cost and Fee Account and the disbursement thereof under the Guidelines Governing
Payment of Attorneys’ Fees and Litigation Costs (Attachments hereto) shall be severable from this
Settlement Agreement, and that regardless of such decision, Plaintiff States will not object to or
oppose approval o f the remainder of the Settlement Agreement by the Court, or otherwise delay or
affect approval o f the settlement, or entry of the Final Judgment and Order. Settling Defendants
agree not to oppose the approval o f the Litigating Plaintiff States’ costs and attorneys’ fees and the
disbursement thereof under the Guidelines Governing Payment o f Attorneys Fees and Litigation
Costs, providing that the Litigating Plaintiff States shall use their best efforts to avoid duplicative,
unreasonable or unnecessary costs and fees in determining the total amount requested to be approved
by the Court, and further provided that Settling Defendants may request the Court to order the
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Litigating Plaintiff States to provide an accounting of costs and fees if they are in good faith
unsatisfied with the Litigating Plaintiff States’ cost and fee summary.
V. SETTLEMENT ADMINISTRATION
A.

The Escrow Agent for the Consumer Fund and State Fund (collectively, the

“Settlement Accounts") shall be determined by the Plaintiff States. The Escrow Agent shall invest
the Consumer Fund and State Fund in obligations of, or obligations guaranteed by, the United States
o f America or any o f its departments or agencies, or in pre-refunded or escrowed municipal bonds
which are federally insured to obtain the highest available return on investment, and shall reinvest
the proceeds o f these instruments as they mature in similar instruments at their then current market
rates. The Escrow Agent shall bear all risks related to the investment o f the escrow funds.
B.

The Settlement Accounts shall be administered pursuant to the Consumer

Distribution Plan, the Government Compensation Plan, the Escrow Agreement, this Settlement
Agreement, and any order o f the Court, as applicable.
C.

All funds held in the Settlement Accounts shall be deemed to be in custodia legis of

the Court, and shall remain subject to the jurisdiction of the Court, until such Settlement Accounts
are fully distributed, or upon further order(s) o f the Court.
D.

Tax Treatment of Settlement Accounts
1.

The Settlement Accounts shall be treated as being at all times “qualified

settlement funds” within the meaning o f Treas. Reg. 1.468B-1. The Escrow Agent, and, as required,
the Parties, shall timely make such elections as necessary or advisable to carry out the provisions of
this Section V.D., including the “relation-back election” (as defined in Treas. Reg. 1.468B-1), back
to the earliest permitted date. Such elections shall be made in compliance with the procedures and
13

requirements contained in such regulation. It shall be the responsibility of the Escrow Agent to
timely and properly prepare and deliver the necessary documentation for signature by all necessary
parties, and thereafter to cause the appropriate filing to occur.
2.

For the purpose of Treas. Reg. 1.468B o f the Internal Revenue Code of 1986,

as amended, and the regulations promulgated thereunder, the “administrator” shall be the Escrow
Agent. The Escrow Agent shall timely and properly file all informational and other tax returns
necessary or advisable with respect to the Settlement Accounts (including, without limitation, the
returns described in Treas. Reg. 1,468B-2(K and L)). Such returns (as well as the election described
in Section V .D .l.) shall be consistent with this Section V.D and in all events shall reflect that all
taxes (including any estimated taxes, interest or penalties) on the income earned by the Settlement
Accounts shall be paid out of the appropriate Settlement Account as provided in Section V.D.3
herein.
3.

All (i) taxes (including any estimated taxes, interest or penalties) arising with

respect to the income earned by a Settlement Account, including any taxes or tax detriments that may
be imposed upon Settling Defendants with respect to any income earned by a Settlement Account
for any period during which such Settlement Account does not qualify as a “qualified settlement
fund” for federal or state income tax purposes (“Taxes”), and (ii) expenses and costs incurred in
connection with the operation and implementation o f this Section V.D (including, without limitation,
expenses o f tax attorneys and/or accountants and mailing and distribution costs and expenses relating
to filing (or failing to file) the returns described in this Section V.D) (“Tax Expenses”), shall be paid
out o f the affected Settlement Account.
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4.

Taxes and Tax Expenses shall be treated as, and considered to be, a cost of

administration of the Settlement and shall be timely paid by the Escrow Agent out of the appropriate
Settlement Account with respect to which such Taxes and/or Tax Expenses have accrued, without
prior order from the Court. The Escrow Agent shall be obligated (notwithstanding anything herein
to the contrary) to withhold from distribution out o f the appropriate Settlement Account any funds
necessary to pay such amounts including the establishment for adequate reserves for any Taxes and
Tax Expenses (as well as any amounts that may be required to be withheld under Treas. Reg.
1.468B-2(1), (2)).
5.

The Parties agree to cooperate with the Escrow Agent, each other, and their

tax attorneys and accountants to the extent reasonably necessary to carry out the provisions o f this
Section V.D. For purposes o f this Section V.D, references to a Settlement Account shall include
such Settlement Account and any earnings thereon.
E.

Settling Defendants will have no responsibility or liability for any distributions o f the

Settlement Accounts or interest earned thereon, or any reporting requirements that may relate
thereto, and no person shall have any claim against any of the Parties, their respective counsel, the
Escrow Agent or any agent designated by the Escrow Agent based on the distributions made
substantially in accordance with this Settlement Agreement and any orders o f the Court.V
I.

VI.
A

SETTLEMENT DISBURSEMENTS

Disbursement o f Administrative Costs:
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1.

Agency Account: The Escrow Agent shall pay from the Agency

Account only those administrative costs and expenses incurred in writing checks and otherwise
incurred in distributing the Agency Account.
2.

Consumer Fund: The Escrow Agent shall pay from the C

Fund all administrative costs and expenses, other than those identified in Section VI.A.l. above,
associated with administering this settlement, including without limitation, costs and expenses
necessary to secure court approval of the Settlement Agreement, such as an expert’s affidavit, costs
and expenses for providing proper notice of this Settlement Agreement, the processing and payment
o f claims and the fees and expenses o f the Escrow Agent.
B.

Distribution to States:
1.

Disbursement o f Attorneys’ Fees and Litigation Costs:

The Escrow Agent shall disburse the Cost and Fee Account in accordance with the Court’s
Final Judgment and Order. Guidelines Governing Payment o f Attorneys’ Fees and Litigation Costs
are included as Attachment 5 to this Settlement Agreement.
2.

Distribution to State Agencies: The Escrow Agent shall distribute all

funds remaining in the Agency Account after payment o f the costs set forth in subsection VI.A.l.
above, according to the Government Compensation Plan. The Government Compensation Plan shall
be consistent with the Guidelines Governing Development o f Government Compensation Plan,
included as Attachment 6 to this Settlement Agreement.
C.

Distribution to Consumers: The Escrow Agent and/or a claims administrator

employed by the Plaintiff States shall distribute and/or administer the distribution o f all funds
remaining in the Consumer Fund after payment o f the costs and expenses set forth in Section VI.A.2
16

above, according to the Court-approved Consumer Distribution Plan. The Consumer Distribution
Plan shall be consistent with the Guidelines Governing Development of Consumer Distribution Plan,
included as Attachment 7 to this Settlement Agreement.
D.

Timing o f Disbursements:
1.

The Escrow Agent shall pay the cost o f administering this Settlement

Agreement, as specified in Section VI.A. above, as these costs accrue, upon submission to the
Escrow Agent o f invoices for these costs as provided in the Escrow Agreement.
2.

The Escrow Agent shall distribute the Cost and Fee Account and the

portion o f the Agency Account not already distributed pursuant to Section VI. A. 1. above, within
thirty (30) days o f the Effective Date.
3.

The Escrow Agent shall, in conjunction with the claims administrator,

begin distributing the portion o f the Consumer Fund not already distributed pursuant to section
VI.A.2. above within thirty (30) days of the Effective Date and shall continue with such distributions
according to the terms of the Court-approved Consumer Distribution Plan until the Consumer Fund
is fully distributed.
VII. NOTICE AND SETTLEMENT HEARING
A.

Within ninety (90) days after execution o f this Settlement Agreement, Liaison

Counsel for Plaintiff States shall file with the Court a motion for Preliminary Approval o f the
Settlement Agreement. This motion shall include this Settlement Agreement and attachments, a
proposed Notice Plan, and the Plaintiff States’ Consumer Distribution Plan and Government
Compensation Plan and the Preliminary Approval Order. The Preliminary Approval Order shall be
substantially in the form of Attachment 3. At least fifteen (15) business days prior to filing their
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motion requesting entry o f the Preliminary Approval Order, the Liaison Counsel for Plaintiff States
shall provide a draft copy of such motion (including all exhibits and attachments o f such motion)
to the Commission and Settling Defendants for review and comment.
B.

Within ninety (90) days after entry by the Court o f the Preliminary Approval Order,

Liaison Counsel for Plaintiff States shall effectuate the Notice Plan.
C.

The Parties contemplate a notice period o f ninety (90) to one hundred twenty (120)

days, or such other time period as set by the Court (“Notice Period”). Within ninety (90) days
following the conclusion of the Notice Period, Liaison Counsel for Plaintiff States shall file with the
Court a motion seeking final approval o f the Final Judgment and Order. The Final Judgment and
Order shall be substantially in the form o f Attachment 2. At least five (5) business days before the
filing o f the Motion for Final Approval, Liaison Counsel for the Plaintiff States shall provide a draft
copy o f such motion (including all exhibits and attachments o f such motion) to the Commission and
Settling Defendants for review and comment. Counsel for all o f the Parties shall use all reasonable
efforts to obtain the entry of the Final Judgment and Order.
VIII. COOPERATION AND IMPLEMENTATION
A.

The Parties, and their respective counsel, agree to use all reasonable practicable

efforts and to take all steps reasonably necessary to effectuate this Settlement Agreement.
B.

The Parties agree that all discovery relating to the Released Claims is stayed and

that such discovery may resume only upon agreement by the Parties or by order o f the Court.
IX. BENEFIT AND BINDING EFFECT
A.

The terms o f this Settlement Agreement shall be binding on, and shall inure to the

benefit of, the Parties and their successors and assigns. The Parties expressly disclaim any intention
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to create rights under this Settlement Agreement which may be enforced by any other person under
any circumstances whatsoever, except as provided in this Settlement Agreement.
B.

The terms o f this Settlement Agreement may be entered into by the Attorney General

of any state who takes the following actions within 30 days o f the execution of this Settlement
Agreement:
1.

Signs an opt-in agreement and signature page which will be appended onto

the body o f the Settlement Agreement which will be filed with the Court; and
2.

Designates the Liaison Counsel for Plaintiff States to represent such state and

agrees to be named as a plaintiff in the Plaintiff States’ Third Amended Complaint.
X.
A.

EFFECT OF TERMINATION OR DISAPPROVAL

If this Settlement Agreement is not approved or is terminated, cancelled, voided or

the Effective Date does not occur for any reason, all monies paid into the Consumer Fund and the
State Fund, and any interest accrued thereon, shall be refunded to Mylan Pharmaceuticals, Inc.,
reduced by the amount of actual out-of-pocket costs and expenses incurred or committed in the
administration o f this Settlement Agreement to the date o f disapproval, cancellation, termination,
voiding or the Effective Date not occurring. Refund to Mylan Pharmaceuticals, Inc. shall occur
within thirty (30) days o f the disapproval, cancellation, termination, voiding or the Effective Date
not occurring. In such event, this Settlement Agreement shall become null and void, shall have no
further force and effect, and the Commission and Plaintiff States shall retain full rights to assert any
and all causes o f action against Settling Defendants, and Settling Defendants shall retain any and all
defenses thereto. These actions shall thereupon revert forthwith to their respective procedural and
substantive status prior to the date o f execution hereof and shall proceed as if this Settlement
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Agreement, and all other related orders and papers, including the Stipulated Permanent Injunction,
had not been executed, and the Parties shall jointly request that any order contemplated hereby,
including the Stipulated Permanent Injunction, which shall have been entered be vacated.
Notwithstanding the foregoing, the provisions o f Section XI. I. shall survive the termination o f this
Settlement Agreement for any reason.
B.

If the Court does not enter the orders or judgments contemplated by this Settlement

Agreement in substantially the form provided herein, or if the Court enters the orders or judgments
and appellate review is sought, and on such review any such order or judgment is materially
modified, then this Settlement Agreement shall be cancelled and terminated, subject to the
provisions o f this Settlement Agreement, unless all Parties to this Settlement Agreement, within
thirty (30) days from the date o f the mailing o f such ruling to such Parties, provide written notice
to all other Parties hereto of their intent to proceed with the settlement.
**•
A.

XI. MISCELLANEOUS

This Settlement Agreement and the Attachments contain the entire agreement and

understanding o f the Parties. There are no additional promises or terms of the Settlement Agreement
other than those contained herein.
B.

The terms or provisions o f this Settlement Agreement may not be changed, waived,

modified, or varied in any manner whatsoever unless in a writing duly signed by all Parties with the
consent o f the Court. Any failure by any party to insist upon the strict performance by any other
party o f any of the provisions o f this Settlement Agreement shall not be deemed a waiver o f any of
the provisions hereof, and that party, notwithstanding that failure, shall have the right thereafter to
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insist upon the strict performance o f any and all o f the provisions o f this Settlement Agreement to
be performed by the other party.
C.

The undersigned counsel for each of the Parties hereby represents that he or she is

authorized to enter into this Settlement Agreement on behalf o f that Party.
D.

The Settlement Agreement shall be deemed to have been mutually prepared by the

Parties hereto and shall not be construed against any o f them solely by reason o f authorship.
E.

The captions contained in this Settlement Agreement are inserted only as a matter

of convenience and in no way define, limit, extend, or describe the scope of this Settlement
Agreement or the intent o f any provision hereof.
F.

The Settlement Agreement may be executed in one or more counterparts.

All

executed counterparts and each o f them shall be deemed to be one and the same instrument. A
complete set o f original executed counterparts shall be filed with the Court.
G.

Any and all notices, requests, consents, directives, or communications by any party

intended for any other party shall be in writing and shall, unless expressly provided otherwise herein,
be given personally, by express courier, or by postage prepaid mail, or by facsimile transmission
followed by postage prepaid mail, and shall be addressed as follows:
To Plaintiff States or the Class:

Chief, Antitrust Section
Office o f the Attorney General
140 East Town Street, 12th Floor
Columbus, OH 43215
To the Commission:
Assistant Director
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Health Care Services and Product Division
Bureau o f Competition
Federal Trade Commission
601 Pennsylvania Avenue, N W
Washington, DC 20580
To Defendants:
Clifford Chance Rogers & Wells LLP
James B. Weidner
200 Park Avenue
New York, New York 10166
Debevoise & Plimpton
Gary W. Kubek
875 Third Avenue
New York, New York 10022
Weil, Gotshal & Manges LLP
Irving Scher
767 Fifth Avenue
New York, New York 10153
Any one o f the Parties may, from time to time, change the address to which such notices, requests,
consents, directives, or communications are to be delivered, by giving the other Parties prior written
notice o f the changed address, in the manner herein above provided, ten (10) calendar days before
the change is effective.
H.

This Settlement Agreement, including, but not limited to, the releases contained

herein, shall be governed by, and construed in accordance with, the laws o f the State of New York
without regard to its conflict o f laws principles. The parties to this Settlement agree that the Final
Judgment and Order shall provide that the Court shall retain jurisdiction to enforce all provisions and
terms o f this Settlement Agreement. This Settlement Agreement shall be enforced in the United
States District Court for the District of Columbia. The Parties, on behalf o f themselves and the
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Settling Members of the Settlement Group, waive any objection that each of them may now have
or hereafter have to the venue of any such suit, action or proceeding and irrevocably consent to the
jurisdiction of the Court and agree to accept and acknowledge service in any such suit, action or
proceeding.
I.

Neither this Settlement Agreement nor any proceedings undertaken in accordance

with the terms set forth herein, shall be construed as or deemed to be evidence of or an admission
or concession by Settling Defendants as to the validity o f any claim that has been or could have been
asserted against them or as to any liability by them, which liability is hereby expressly denied and
disclaimed by Settling Defendants. Neither this Settlement Agreement, nor any o f its provisions,
nor any statement or document made or filed in connection herewith, shall be filed, offered, received
in evidence or otherwise used in any action or proceeding or in any arbitration, except in connection
with the Parties’ application for approval or enforcement o f this Settlement Agreement and all
proceedings incident thereto, including requests for attorneys’ fees, costs and disbursements and
compensation to Litigating Plaintiff States.
J.

Within thirty (30) days after the Effective Date, the Commission and the Plaintiff

States shall return all materials and documents produced in these actions by any party or non-party
to the person or entity that produced those documents or, upon written request by that person or
entity, shall have those documents destroyed. In the event that documents are destroyed, the Plaintiff
States shall provide prompt notice to the person or entity that produced those documents, certifying
their destruction. In the event that the Plaintiff States or the Commission are requested by subpoena
or other legal process to provide such information to any person, they shall immediately inform the
Settling Defendants of the subpoena or legal process, shall decline to waive any such privileges and
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objections to disclose as may exist, and shall reasonably cooperate with the Settling Defendants who
shall have the right and responsibility to challenge such subpoena or legal process. The obligations
of the Plaintiff States and the Commission are governed by the Court’s Protective Order entered
March 16, 1999.
K.

Notwithstanding Section XI.I above, this Settlement Agreement may be pleaded as

a full and complete defense to any action, suit or other proceeding that has been or may be instituted,
prosecuted or attempted with respect to any of the Released Claims. The Parties agree that for any
such proceeding, the Court or any court of competent jurisdiction may enter an injunction restraining
prosecution o f such proceeding. The Parties further agree that this Settlement Agreement may be
pleaded as necessary for the purpose o f enforcing the Settlement Agreement.

FOR MYLAN LABORATORIES, INC. and
MYLAN PHARMACEUTICALS, INC.

eidner, Esq.
Clifford Chance Rogers & Wells LLP
200 Park Avenue
New York, New York 10166
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FOR GYMA LABORATORIES OF
AMERICA, INC.

New York, N.Y. 10153

FOR PROFARMACO S.R.L. and
CAMBREX CORP.

Gary W. Kubek, Esq.
Debevoise & Plimpton
875 Third Avenue
New York, N.Y. 10022
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FOR GYMA LABORATORIES OF
AMERICA, INC.

David Hickerson, Esq.
Weil, Gotshal & Manges LLP
1615 L Street N.W., Suite 700
Washington, D.C. 20036

FOR PROFARMACO S.R.L. and
CAMBREX CORP.

Christopher K. Tahbaz, Esq.
Debevoise & Plimpton
875 Third Avenue
New York, New York 10022
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Antitrust Bureau
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ATTACHMENT 1
FINAL ESCROW AGREEMENT
THIS FINAL ESCROW AGREEMENT, dated as of January
2001 ("Final Escrow"), is
entered into by the State of Ohio as liaison counsel, through its Attorney General, on behalf of the States
of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of
Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon,
Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia,
Washington, West Virginia, Wisconsin and Wyoming (herein referred to as "Plaintiff States"), Mylan
Pharmaceuticals, Inc. ("Mylan"), SST Corporation ("SST") and Fifth Third Bank, as Escrow Agent
hereunder ("Escrow Agent").
WHEREAS:
The Plaintiff States, the Federal Trade Commission, and defendants Mylan Laboratories Inc.Gyma
Laboratories of America, Inc.,ProfarmacoS.r.l., and Cambrex Corp. have entered into a settlement agreement
(the "Settlement") pursuant to which litigation by the Plaintiff States and the Federal Trade Commission
against these defendants will be resolved, upon Court approval,and under which Mylan has paid pursuant to
an interim escrow agreement ("Interim Escrow", attached hereto as exhibit A), c/o the Escrow Agent,
$28,217,983 into the Mylan Antitrust Action State Claims Account 28 28 002 6013106 (the "State Fund")
and $71,782,017 into the Mylan Antitrust Action Consumer Claims Account 2828 002 6013098 (the
"Consumer Fund"), and Mylan has agreed to pay up to an additional $8,000,000 to the Cost and Fee Account
for fees and costs of litigation incurred by the Litigating Plaintiff States;
•¿ft.

A settlement agreement (the "SST Settlement") has also been entered into between the Plaintiff States
and defendant SST that provides that SST shall pay, c/o the Escrow Agent, at least $500,000 as follows:
$108,750 into the SST Agency Account, $266,250 into the SST Consumer Fund, and at least $125,000, plus
certain additional funds that may accrue to the Plaintiff States as a result of SST's settlement with the Plaintiff
States and proposed settlements with private plaintiffs, into the SST Cost and Fee Account;
Plaintiff States have appointed the Attorney General of the State of Ohio as Liaison Counsel (as
defined below) to represent them in connection with the litigation and the settlement thereof, and;
Counsel for the Plaintiff States, by and through the Plaintiff States' Liaison Counsel, agree to appoint
Fifth Third Bank as the Escrow Agent, and Fifth Third Bank is willing to act as Escrow Agent hereunder in
accordance with the terms and conditions of this Final Escrow. In order to administer the Escrow Funds (as
defined below), the parties hereto have entered into this Final Escrow.
STATEMENT OF AGREEMENT
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto, for themselves, their successors and assigns, hereby agree to
the foregoing and as follows:1
1.

Definitions:

I

a.
All capitalized terms used herein shall have the same meaning as
for in the Settlement or SST Settlement, whichever is applicable, unless the capitalized term is expressly
defined herein.
b.
"Written Direction" shall mean a written notification, signed by the Plaintiff
States' Representatives, in the form attached hereto as Exhibit B. Each Written Direction shall include a
certification by the Plaintiff States' Representatives that the instructions in the notification are being made
pursuant to the terms of the Settlements and this Final Escrow.
c.
"Escrow Funds" shall mean (i) the funds deposited by Mylan with the
Escrow Agent pursuant to the Interim Escrow including interest earned thereon (defined in the Interim Escrow
therein as "Escrow Amounts"), (ii) funds deposited pursuantto this Final Escrowto the Cost and Fee Account,
the SST Agency Account, the SST Consumer Fund, and the SST Cost and Fee Account, and (iii) any and all
earnings and/or interest from investment of the Escrow Funds.
d.
"Liaison Counsel for the Plaintiff States" or "Liaison Counsel" means the
State of Ohio, through Betty D. Montgomery, Attorney General, or any other person or persons designated
by her or any official successor.
e.
"Plaintiff States' Representatives" shall mean Betty D. Montgomery,
Attorney General of the State of Ohio, and J. JosephCurran, Jr., Attorney General of the State of Maryland,
or any other person or persons designated by them or any official successors.
f.

"Settlements" shall mean the Settlement and the SST Settlement.

2.
Appointment of and Acceptance bv Escrow Agent. The Plaintiff States'
Representatives hereby appoint Fifth Third Bank to serve as the Escrow Agent hereunder. Escrow Agent
hereby accepts such appointgientand agrees to hold, invest and disburse all Escrow Funds in accordance with
this Final Escrow.
3.

Distribution Accounts.

a.
In addition to the State Fund and the Consumer Fund already established
under the Interim Escrow, Escrow Agent shall separately establish the SST State Fund and the SST Consumer
Fund (collectively, the "Accounts").
b.
Escrow Agent shall establish two (2) segregatedsubaccounts within the State
Fund: the Agency Account and the Cost and Fee Account. Mylan shall fund the Cost and Fee Account by
wire transfer pursuant to the Final Order within five (5) business days following entry of the Final Order.
Escrow Agent shall segregate the payment already made by Mylan to the State Fund pursuant to the Interim
Escrow, including interest thereon, into the Agency Account. Escrow Agent shall continue to maintain the
Consumer Fund separately. Escrow Agent shall also account separately for the interest earned upon the Cost
and Fee Account, Agency Account, and the Consumer Fund.
c.
SST shall fund by wire transfer the SST Consumer Fund within twenty (20)
days after preliminary approval of the SST Settlement. Escrow Agent shall establish two (2) segregated
subaccounts within the SST State Fund: the SST Agency Account and the SST Cost and Fee Account. SST
shall fund by wire transfer the SST Agency Account within twenty (20) days after preliminary approval of
the SST Settlement. SST shall wire transfer $125,000 to the SST Cost and Fee Account within twenty (20)
days after preliminary approval of the SST Settlement. Any additional funds accruing to the Plaintiff States
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pursuant to SST's settlement with the Plaintiff States and proposed settlements with private plaintiffs shall be
transferred to the SST Cost and Fee Account within twenty (20) days of such funds accruing to the Plaintiff
States. Escrow Agent shall account separately for the interest earned upon the SST Cost and Fee Account,
the SST Agency Account, and the SST Consumer Fund.
4.

Disbursement of Escrow Funds.

a.
The Escrow Agent shall disburse Escrow Funds solely as provided for herein
or by order of the Court. At the Effective Date,as defined in the Mylan Settlement Agreement, which is
incorporated herein as Exhibit D, the Plaintiff States and Mylan shall jointly instruct the Escrow Agent, in
writing, that it may disburse funds from the Consumer Fund and State Fund pursuant to this Paragraph 4c, d
and e. At the Effective Date, as defined in the SST Settlement Agreement, which is incorporated herein as
Exhibit E, the Plaintiff States and SST shall jointly instruct the Escrow Agent, in writing, that it may disburse
funds from the SST Consumer Fund and SST State Fund pursuant to this Paragraph 4c, d and e.
b.
Escrow Agent shall pay from the Consumer Fund the costs and expenses
associated with administering the Settlements, including, without limitation, costs and expenses for providing
proper notice of the Settlements, expert or consulting fees, the processing and payment of claims, and the fees
and expenses of the Escrow Agent; except those expenses incurred in writing checks and distribution of the
Agency Account shall be paid from the Agency Account. Taxes and Tax Expenses shall be paid as provided
for in Paragraph 8 below.
c.
Escrow Agent shall distribute Escrow Funds for compensation to natural
persons only from the Consumer Fund and the SST Consumer Fund. Escrow Agent shall distribute the
Consumer Fund for compensation to natural persons upon Written Direction from Plaintiff States'
Representatives. Escrow Agent shall distribute the SST Consumer Fund to natural persons upon Written
Direction from Plaintiff States' Representatives. If requested by Plaintiff States' Representatives, and if
approved by the Court, Escrow Agent shall distribute any residue and/or interest remaining in the Consumer
Fund and/or the SST Consumer Fund to the Litigating Plaintiff States forcy pres distribution by their
respective Attorneys General.
d.
Escrow Agent shall distribute Escrow Funds for compensation to state
agencies only from the Agency Account and the SST Agency Account. Escrow Agent shall distribute the
Agency Account for compensation to state agencies upon Written Direction from Plaintiff States'
Representatives. Escrow Agent shall distribute the SST Agency Account for compensation to state agencies
upon Written Direction from Plaintiff States' Representatives.
e.
Escrow Agent shall distribute Escrow Funds for reimbursement of attorney
fees and costs incurred by Litigating Plaintiff States, and/or contribution to the NAAG Milk Fund, solely from
the Cost and Fee Account and the SST Cost and Fee Account. Escrow Agent shall distribute the Cost and Fee
Account for such reimbursement and/or contribution upon Written Direction from Plaintiff States'
Representatives. Escrow Agent shall distribute the SST Cost and Fee Account for such reimbursement and/or
contribution upon Written Direction from Plaintiff States' Representatives.
5.
Cooperation with Other Parties. Escrow Agent shall, at the direction of the Plaintiff
States' Representatives, cooperate with and provide all account and other necessary information to any
company or person employed by the Plaintiff States to administer a consumer claims procedure, including any
cooperation necessary for the issuance of consumer refund checks by such claims administrator.
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6.
Termination of Settlement Agreement. If the Settlement is not approved or is
terminated, cancelled, voided or the Effective Date does not occur for any reason (Terminating Event”), all
Escrow Funds paid by Mylan (and interest thereon) shall be refunded to Mylan, reduced by the actual out-ofpocket costs and expenses incurred or committed in the administration of the Settlements to the date of the
Terminating Event. In such case, refund shall occur within thirty (30) days of notification of the Terminating
Event, in writing, from Mylan and the Plaintiff States’Representatives to the Escrow Agent. If the SST
Settlement is not approved or is terminated, cancelled, voided or the Effective Date of the SST Settlement does
not occur for any reason ("SST Terminating Event"),all Escrow Funds paid by SST (and interest thereon)
shall be refunded to SST. In such case, refund shall occur within thirty (30) days of notification of the SST
Terminating Event, in writing, from SST and the Plaintiff States’Representatives to the Escrow Agent. The
refund to Mylan and/or SST shall be reduced by the pro-rata share of any Taxes and Tax Expenses (as those
terms are defined below) paid or owed by the effected Account(s) through, as applicable, the date of the
Terminating Event and/or the SST Terminating Event.
7.
Investment of Escrow Funds. Escrow Agent shall, in accordance with Written
Directions, invest the Escrow Funds in obligations of, or obligations guaranteed by, the United States of
America or any of its departments or agencies, or in pre-refunded or escrowed municipal bonds which are
federally insured, to obtain the highest available return on investment, and shall reinvest the proceeds of these
instruments as they mature in similar instruments at their then current market rates. Escrow Agent shall bear
all risks related to the investment of Escrow Funds. The Escrow Funds shall be deemed and considered to be
in custodia legis of the Court, and shall remain subject to the jurisdiction of the Court, until such time as such
Escrow Funds are fully distributed or upon further order(s) of the Court.
8.
Preparation and Payment of Taxes. Escrow Agent shall establish andtreat the
Accounts as each being at all times a separate "qualified settlement fund" within the meaning of Treas. Reg.
§1.468B-1, and ensure that each Account is treated as a separate taxpayer. In addition, Escrow Agent and,
as required, the parties hereto shall jointly and timely make such elections as necessary or advisable to carry
out the provisions of the Settlements, including the "relation-back election" (as defined in Treas. Reg.
§ 1.468B-1), back to the earliest permitted date. Such elections shall be made in compliance with the
procedures and requirements contained in such regulation. It shall be the responsibility of Escrow Agent to
timely and properly prepare and deliver the necessary documentation for signature by all necessary parties,
and thereafter to cause the appropriate filing(s) to occur. For the purpose of § 468B of the Internal Revenue
Code of 1986, as amended, and the regulations promulgated thereunder, the "administrator" shall be the
Escrow Agent. Escrow Agent shall timely and properly file all informational and other tax returns necessary
or advisable with respect to each Account (including without limitation the returns described in Treas. Reg.
§1.468B-2 K and L). Such returns shall reflect that all taxes (including any estimated taxes, interest or
penalties) on the income earned by each Account shall be paid by the effected Account. All (i) taxes
(including any estimated taxes, interest or penalties) arising with respect to the income earned by an Account,
including any taxes or tax detriments that may be imposed upon Mylan and/or SST with respect to any income
earned by that Account for any period during which that Accountdoes not qualify as a "qualified settlement
fund" for federal or state income tax purposes ("Taxes"), and (ii) expenses and costs incurred in connection
with the operation and implementation of this paragraph (including, without limitation, expenses of tax
attorneys and/or accountants and mailing and distribution costs and expenses relating to filing (or failing to
file) the returns described herein) ("Tax Expenses"), shall be paid out of effected Account. Further, Taxes and
Tax Expenses shall be treated as, and considered to be, a cost of administration of the Settlements and shall
be timely paid by Escrow Agent out of the effected Account without prior order from the Court, and Escrow
Agent shall be obligated (notwithstanding anything herein to the contrary) to withhold from distribution to
Plaintiff States any monies necessary to pay such amounts including the establishment for adequate reserves
for any Taxes and Tax Expenses (as well as any amounts that may be required to be withheld under Treas.
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Reg. §1.468B-2(1), (2)); Mylan and SST are not responsible and shall have no liability therefor or for any
reporting requirements that may relate thereto. The parties hereto agree to cooperate with the Escrow Agent,
each other, and their tax attorneys and accountants to the extent reasonably necessary to carry out the
provisions of this paragraph. Escrow Agent shall be responsible for and liable for any negligence in
preparation and filing of Taxes and Tax Expenses (including, without limitation, taxes payable by reason of
such negligence).
9.
Resignation and Removal of Escrow Agent. Escrow Agent may resign from the
performance of its duties hereunder at any time by giving sixty (60) days prior written notice to the Plaintiff
States' Representatives or may be removed, with or without cause, by the Plaintiff States' Representatives, by
furnishing thirty (3 0) days prior written notice to Escrow Agent. Such resignation or removal shall take effect
upon the appointment of a successor Escrow Agent as provided herein. Upon any such notice of resignation
or removal, the Plaintiff States' Representatives shall appoint a successor Escrow Agent hereunder, subject
to the approval of Mylan and SST. Upon the acceptance in writing of any appointment as Escrow Agent
hereunder by a successor Escrow Agent, such successor Escrow Agent shall thereupon succeed to and become
vested with all the rights, powers, privileges and duties of the retiring Escrow Agent, and the retiring Escrow
Agent shall be discharged from its duties and obligations under this Final Escrow, but shall not be discharged
from any liability for actions taken as Escrow Agent hereunder prior to such succession. The retiring Escrow
Agent shall transmit all records pertaining to the Escrow Funds and shall pay all Escrow Funds to the
successor Escrow Agent, after making copies of such records as the retiring Escrow Agent deems advisable
and after deduction by and payment to the retiring Escrow Agent (after written notice to Plaintiff States'
Representatives) o f all fees and expenses incurred by or expected to be incurred by the retiring Escrow Agent
in connection with the performance of its duties and the exercise of its rights hereunder.
10.
Liability of Escrow Agent. The duties and obligations of the Escrow Agent shall be
determined by the express provisions of this Final Escrow and the Settlements, and no implied duties or
obligations shall be inferred or otherwise imposed upon or against the Escrow Agent, and the Escrow Agent
shall not be liable except for the performance of such duties and obligations as are specifically set out in this
Final Escrow and the Settlements.

11.

Fees and Expenses of Escrow Agent.

a.
The Escrow Agent shall be compensated for its services hereunder in
accordance with Exhibit C attached hereto, pursuant to the bid accepted by Liaison Counsel.
b.
Escrow Agent is authorized to, and may disburse, to itself the amount of any
compensation due and payable hereunder in accordance with Paragraph 4(b) above and this Paragraph. Such
compensation may be directly disbursed by the Escrow Agent to itself on a monthly basis, thirty (30) days
after giving written notice, consisting of an itemization of compensation earned, and copies of invoices, to the
Plaintiff States' Representatives and Mylan.
12.
Reports and Accounting. Escrow Agent will provide monthly reports to Plaintiff
States' Representatives, and, if requested, to Mylan and SST, in a form that is acceptable to the Plaintiff States'
Representatives, reflecting income and disbursement activity of the Escrow Funds for the period and year to
date. The Escrow Agent shall further issue a final report and accounting which will summarize the income,
expenses, and disbursements associated with the administration of the Escrow Funds and such other reports
as the Plaintiff States' Representatives may reasonably require from time to time. Escrow Agent shall provide
copies of the final report and accounting to Mylan and SST. Reports and the status of all accounts shall be
accessible to the Plaintiff States' Representatives on-line. The Escrow Agent will provide the name of the
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officer who will have principal responsibility of the management of the Escrow Funds and the Escrow Agent's
relationship with the Office of the Ohio Attorney General.
13.
Consent to Jurisdiction and Venue. In the event that any party hereto commences
a lawsuit or other proceeding relating to or arising from this Escrow Agreement, the parties hereto agree that
the District Court for the District of Columbia shall have the sole and exclusive jurisdiction over any such
proceedings. Such Court shall have proper venue for any such lawsuit or judicial proceeding and the parties
hereto waive any objection to such venue. The parties hereto consent to and agree to submit to the jurisdiction
of such court and agree to accept service of process to vest personal jurisdiction over them in such Court.
14.
Notices. All notices and other communications hereunder shall be in writing and
shall be deemed to have been validly served, given or delivered five (5) days after deposit in the United States
mails, by certified mail with return receipt requested and postage prepaid, when delivered personally, one (1)
day after delivery to any overnight courier, or when transmitted by facsimile transmission facilities, and
addressed to the party to be notified as follows:
If to Plaintiff States at:

•*

Doreen C. Johnson
Chief, Antitrust Section
Mitchell L. Gentile
Principal Attorney
Office of the Ohio Attorney General
140 East Town Street, 12th Floor
Columbus, Ohio 43215
Meredyth Andrus
Assistant Attorney General
Office of the Attorney General of Maryland
Antitrust Division
200 St. Paul Place, 19th Floor
Baltimore, Maryland 21202-2021

If to Mylan at:

James B. Weidner
Clifford Chance Rogers & Wells LLP
200 Park Avenue
New York, New York 10166-0153

If to SST at:

Sidney S. Rosdeitcher
Paul, Weiss, Rifkind, Wharton & Garrison
1285 Avenue of the Americas
New York, New York 10019-6064

If to Escrow Agent at:

Fifth Third Bank
Frank Wojcik
Vice President
21 East State Street
Columbus, Ohio 43215

or to such other address as each party may designate for itself by like notice.
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15.
Rights to Account. Neither the Plaintiff States, their agencies or departments, nor
any member of anyparens or consumer class, shall have any rights or title to or interest in any portion of any
Escrow Funds or Accounts except as provided by order of the Court.
*

16.
Amendment or Waiver. This Final Escrow may be changed, waived, discharged or
terminated only by a writing signed by Liaison Counsel for the Plaintiff States, Mylan, SST, and the Escrow
Agent. No delay or omission by any party in exercising any right with respect hereto shall operate as a waiver.
A waiver on any one occasion shall not be construed as a bar to, or waiver of, any right or remedy on any
future occasion. Escrow Agent agrees to enter into an amendment of this Final Escrow with respect to the
treatment, designation, and/or use of the Escrow Funds, including, without limitation, the tax treatment of the
Escrow Funds, should such amendment be deemed warranted by Plaintiff States' Representatives, Mylan and
SST.
17.
Governing Law. This Final Escrow shall be construed and interpreted in accordance
with the laws of the State of Ohio without giving effect to the conflict of laws principles thereof.
18.
Entire Agreement. This Final Escrow and the Settlements constitute the entire
agreement between the parties relating to the holding, investment and disbursement of the Escrow Funds and
set forth in their entirety the obligations and duties of Escrow Agent with respect to the Escrow Funds.
19.
Binding Effect. All of the terms of this Final Escrow, as may be amended from time
to time, shall be binding upon, inure to the benefit of and be enforceable by the parties hereto and their
respective heirs, successors and assigns.
20.
Execution in Counterparts. This Final Escrow may be executed in two or more
counterparts, which when so executed shall constitute one and the same agreement.
21.
Dealings. Nothing herein shall preclude the Escrow Agent from acting in any other
capacity for any party, person or entity referenced herein.
IN WITNESS WHEREOF, the parties hereto have caused this Final Escrow to be executed
under seal as of the date first above written.
PLAINTIFF STATES

By:______________________________________
Title: Director of Administration for Liaison Counsel

MYLAN PHARMACEUTICALS, INC.

By:_____________________________
Counsel for Mylan Pharmaceuticals, Inc.
SST CORPORATION
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B y:_____________________

Counsel for SST Corporation
FIFTH THIRD BANK
By:_______________

Title: Vice President
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EXHIBIT B
JOINT WRITTEN DIRECTION
EXAMPLE
STATE OF CONNETICUT ET AL V MYLAN PHARMACEUTICALS ET AL
ESCROW #

In accord with the Final Escrow Agreement, d ated__________________ , 2001 and the
Settlement Agreements referenced in the Escrow Agreement, the Plaintiff States' Representatives
d irect____________________________ as the Escrow Agent to take the following action with
respect to the Escrow Funds. The Escrow Agent shall:

D A TED :_____________

. 2001

PLAINTIFF STATES

By:

B y :_________________________
Plaintiffs' States’ Representatives
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Exhibit C
Schedule of Fees and Expenses

Out of Pocket Expenses:

$0 (Absorbed in the Administrative Fee)

Annual Administration Fee:

$20,000

Investment Fee:
For Interest-Bearing or Money
Market Account:

3 basis points

For purchases o f
Treasury Securities:

(.0003) times average annual

$0

Other:

$0

Fifth Third Bank
21 East State Street
Columbus, Ohio 43215
Attention: Frank Wojcik
(614) 233-4413

Schedule of Fees and Expenses Exhibit C
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Assets.

ATTACHMENT 2
UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

)
)
)
)
)
) Civ. No. L98-CV-3114 (TFH)

THE FEDERAL TRADE COMMISSION,
Plaintiff,

)
)
)
)
)
)
Defendants.
)
.)
)
THE STATE OF CONNECTICUT, et al.
)
)
Plaintiffs,
)
)
v.
) Civ. No. L98-CV-3115 (TFH)
)
MYLAN LABORATORIES, INC.,
)
CAMBREX CORP.,
)
PROFARMACO S.R.L.,
)
GYMA LABORATORIES OF AMERICA, INC., )
and SST CORP.,
)
Defendants.
)
)
MYLAN LABORATORIES, INC.,
CAMBREX CORP.,
PROFARMACO S.R.L., and
GYMA LABORATORIES OF AMERICA, INC.,

[PROPOSED! FINAL JUDGMENT AND ORDER
W H EREA S the States o f Alabama, Alaska, Arizona, Arkansas, California, Colorado,
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Louisiana,
Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New
!

Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma,
Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont,
Washington, West Virginia, Wisconsin, Wyoming, and the Commonwealths o f Kentucky,
Massachusetts, Pennsylvania, and Virginia, through their Attorneys General, and the District of
Columbia through its Corporation Counsel (“Plainitff States” as defined below), and the Federal
Trade Commission, have filed Complaints for damages, divestment, disgorgement, restitution and
other equitable relief, injunctive relief, and civil penalties against the defendants Mylan Laboratories,
Inc., Gyma Laboratories of America, Inc., Profarmaco S.r.l., and Cambrex Corp., alleging violations
o f the Sherman Act, Federal Trade Commission Act, and state antitrust and unfair competition
and/or consumer protection laws.
WHEREAS Plaintiff States, the Commission and Settling Defendants desire to resolve any
and all disputes arising from the Complaints. The parties executed a settlement agreement on
■*A.

_____________(the “Mylan Settlement Agreement”). The Mylan Settlement Agreement was filed
with the Court o

n

________. 2001. The Mylan Settlement Agreement does not constitute any

evidence against or an admission o f liability by the Settling Defendants.
WHEREAS in full and final settlement o f the claims set forth in the Complaints, Mylan
Pharmaceuticals, Inc. has paid $100 million in cash, of which $71,782,017.00 was paid into a
Consumer Fund, to be distributed in accordance with the Consumer Distribution Plan, and of which
$28,217,983.00 was paid into a State Fund, to be distributed in accordance with the Government
Compensation Plan, as set forth in the Mylan Settlement Agreement. Mylan Pharmaceuticals, Inc.
has further agreed to pay up to $8 million in cash into the Cost and Fee Account, as set forth in the
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My lan Settlement Agreement. Settling Defendants have also agreed to entry o f this Final Judgment
and Order.
W HEREAS the Commission and Settling Defendants have entered into a Stipulated
Permanent Injunction, which was approved by the Commission on November 29,2000, Attachment
4 to the Mylan Settlement Agreement, incorporated herein by reference.
W H EREA S the Plaintiff States have also filed a Complaint for damages, divestment,
disgorgement, restitution and other equitable relief, and civil penalties against SST Corporation
(“SST”), alleging violations o f the Sherman Act and state antitrust and unfair competition and/or
consumer protection laws (“SST Complaint”).
W H EREA S the Plaintiff States and SST Settling Defendant desire to resolve any and all
disputes arising from the SST Complaint.

The parties executed a settlement agreement on

___________ ,2001 (the “SST Settlement Agreement”). The SST Settlement Agreement was filed
with the Court o n ___________, 2001. The SST Settlement Agreement does not constitute any
evidence against or an admission o f liability by SST Settling Defendant.
W H EREA S in full and final settlement o f the claims set forth in the SST Complaint, SST
has paid to the Plaintiff States $500,000, c/o the Escrow Agent appointed pursuant to the Settlement
Agreements, and the Plaintiff States’ share of the $1 million payment made pursuant to SST’s
settlement in the Advocate Action. SST Settling Defendant has also agreed to the entry of this Final
Judgment and Order.
W H EREA S Plaintiff States have agreed to release the claims of consumers residing in the
Plaintiff States who have not submitted valid and timely requests for exclusion from the Settlement
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Group in accordance with the instructions contained in the Notice, and the Commission has agreed
to release its equitable claims.
WHEREAS pursuant to a Preliminary Approval Order, Notice of the Settlement Agreements
was given to the Settlement Group pursuant to Court order in accordance with Federal Rules o f Civil
Procedure 23(c)(2) and 23(e), state parens patriae laws and/or state equitable authority and the
requirements of due process.
WHEREAS an opportunity to be heard was given to all members o f the Settlement Group
requesting to be heard in accordance with this Court's orders.

The Court has reviewed and

considered the terms of the Settlement Agreements, the submissions o f the parties in support thereof,
and the comments received in response to the Notice. After holding a hearing o n _____________ .
2001 at which all interested parties were given an opportunity to be heard,
NOW, THEREFORE, before the taking of any testimony, without trial or adjudication of
any issue o f fact or law herein, without any admission o f liability or wrongdoing by Settling
Defendants or SST Settling Defendant and upon the consent o f the Parties hereto, IT IS HEREBY
ORDERED, ADJUDGED AND DECREED:
I. JURISDICTION
The Court has jurisdiction over the subject matter o f this action and the parties hereto. The
Plaintiff States brought this action asserting claims under Sections 1 and 2 o f the Sherman Act, 15
U.S.C. §§ 1 and 2, and claims under state antitrust, unfair competition and consumer protection
statutes, and common law. The Commission brought this action under Sections 5 and 13(b) o f the
Federal Trade Commission Act, 15 U.S.C. §§ 45 and 53(b). Jurisdiction lies in this Court pursuant
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to 28 U.S.C. §§ 1331, 1337 and 1367(a). Venue is proper in the District ofthe District of Columbia.
II. DEFINITIONS
As used in this Final Judgment and Order, the following definitions shall apply:
A.

“Advocate Action” means the action entitled Advocate Health Care, et al. v. Mylan

Laboratories, Inc., et al., which is one of the coordinated cases in In re Lorazepam and Clorazepate
Antitrust Litigation, Case No. MDL-1290 in this Court.
B.

“Agency Account” means a separate account, established within the State Fund,

funded and distributed as specified in the Mylan Settlement Agreement.
C.

“Class” means the class certified for settlement purposes only as provided in Section

IV. hereof.
D.

“Commission” means the Federal Trade Commission.

E.

“Commission’s Complaint” means the complaint filed by the Commission on

December 21, 1998, as amended on February 8, 1999, against Settling Defendants in the United
States District Court for the District o f Columbia.
F.

“Consumer Distribution Plan” means the plan and method o f allocation o f the

Consumer Fund and the SST Consumer Fund submitted for this Court’s approval by the Plaintiff
States.
G.

“Consumer Fund” means an interest-bearing escrow account, established pursuant

to the Escrow Agreement, administered by the Escrow Agent and funded and distributed as set forth
in the Mylan Settlement Agreement.
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H.

“Cost and Fee Account” means a segregated account established within the State

Fund and funded as set forth in the Mylan Settlement Agreement.
I.

“Court” means the United States District Court for the District of Columbia.

J.

“Escrow Agent” means the person or entity chosen by the Plaintiff States and

designated pursuant to the Escrow Agreement to administer the Consumer Fund and State Fund as
set forth in the terms o f the Mylan Settlement Agreement, and the SST Consumer Fund and SST
State Fund as set forth in the terms o f the SST Settlement Agreement.
K.

“Escrow Agreement” means the escrow agreement, attached to the Settlement

Agreements as Attachment 1.
L.

“Government Compensation Plan” means the plan and method o f allocation o f the

State Fund and the SST State Fund submitted for this Court’s Approval by the Plaintiff States.
M.

’’Litigating Plaintiff States” means the 33 Plaintiff States that participated in the

litigation and negotiation o f the settlements o f these actions: Alaska, Arkansas, California, Colorado,
Connecticut, District o f Columbia, Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine,
Maryland, Michigan, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio,
Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont,
Washington, West Virginia, and Wisconsin.1
N.

“Mylan Settlement Agreement” means the Settlement Agreement between Plaintiff

1For purposes o f the litigation and this settlement, the definition of “Litigating Plaintiff
States” or “Plaintiff States” does not include the University o f California. It is stipulated by the
Parties that the California Attorney General has not represented the interests of the University o f
California in the litigation or the settlement thereof, and the University o f California has not been
participating in this action.
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States, the Federal Trade Commission and Mylan Laboratories, Inc., Gyma Laboratories of America,
Inc., Profarmaco S.r.l., and Cambrex Corp.
O.

“Notice” means the notice or notices o f these. Settlement Agreements and hearing

thereof that were disseminated to the members o f the Settlement Group pursuant to this Court’s
Order o f
P.

“Notice Plan” means the Court-approved process by which the Plaintiff States

notified the Settlement Group o f the Settlement Agreements.
Q.

“Parties” means Plaintiff States, the Commission, Mylan Laboratories, Inc., Gyma

Laboratories o f America, Inc., Profarmaco S.r.l., Cambrex Corp. and SST Corporation.
R.

“Person” means any natural person, partnership, corporation, or business entity.

S.

“Plaintiff States” means the Litigating Plaintiff States and any State that became a

party to the Settlement Agreements, through the State’s Attorney General, individually and as
authorized by law, in the state’s sovereign capacity, on behalf o f state agencies, in a statutory,
equitable and/or common law capacity, and as representative of and/or parens patriae on behalf of
all natural person citizens o f such State who purchased either or both of the Relevant Drugs during
the Relevant Period.
T.

“Plaintiff States’ Complaint” means the complaint filed by the Litigating Plaintiff

States on December 21, 1998, as amended on February 8, 1999 and again on May 13,1999 and the
Third Amended Complaint filed by the Plaintiff States o n ___________ ,2001.
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U.

“Preliminary Approval Order” means the Court's Order o f ______________ , 2001

preliminarily approving the Settlement Agreements and establishing a schedule for Notice and
further proceedings.
V.

“Released Claims” means all claims, counterclaims, set-offs, demands, actions, rights,

liabilities, and causes of action arising under federal or state antitrust, unfair methods of competition,
or consumer protection laws, under state or federal unfair or deceptive trade practices acts, or under
common law, asserted or that could have been asserted, by the Commission, by Settling Members
o f the Settlement Group, or by the Plaintiff States on behalf o f state agencies and/or natural person
consumers within the Plaintiff States against Settling Defendants and SST Settling Defendant arising
from the facts, matters, transactions, events, occurrences, acts, disclosures, statements, omissions,
or failures to act set forth or alleged in the Commission’s Complaint or in the Plaintiff States’
Complaint.
W.

“Relevant Drugs” means generic lorazepam or clorazepate sold in the United States.

X.

“Relevant Period” means the period from January 1, 1998 through December 31,

Y.

“Settlement Agreements” means the Mylan Settlement Agreement and the SST

1999.

Settlement Agreement.
Z.

“Settlement Group” means all natural person consumers represented by Attorneys

General for the Plaintiff States, individually and as authorized by law in a statutory, equitable and/or
common law capacity, as parens patriae and/or as representatives o f the Class.
AA.

“Settling Defendants” means Mylan Laboratories, Inc. (“Mylan”), Gyma Laboratories
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o f America, Inc. (“Gyma”), Profarmaco S.r.l. (“Profarmaco”), Cambrex Corp. (“Cambrex”), and any
and all o f their affiliates, subsidiaries, divisions and other organizational units o f any kind, their
successors and assigns, and their former, current and future officers, directors, employees, agents,
attorneys, representatives, shareholders, partners and other persons acting on their behalf.
BB.

“Settling Members o f the Settlement Group” means each and every member o f the

Settlement Group who did not exercise his or her right to exclude himself or herself from the
Settlement Group pursuant to a proper written request for exclusion postmarked on or before
________ , 2001.

CC.

“SST” or “SST Corporation” means SST Corporation, a New Jersey Corporation

with its principal place o f business in Clifton, New Jersey.
DD.

“SST Agency Account” means a separate account established within the SST

State Fund, funded and distributed as specified in the SST Settlement Agreement.
EE.

“SST Consumer Fund” means an interest-bearing escrow account established

pursuant to the Escrow Agreement, administered by the Escrow Agent and funded and distributed
as set forth in the SST Settlement Agreement.
FF.

“SST Cost and Fee Account” means a segregated account established within the SST

State Fund and funded as set forth in the SST Settlement Agreement.
GG.

“SST Settlement Agreement” means the Settlement Agreement between Plaintiff

States and SST Corporation.
HH.

“SST Settling Defendant” means SST Corporation, and any and all o f its affiliates,

subsidiaries, divisions and other organizational units o f any kind, their successors and assigns, and
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the former, current and future officers, directors, employees, agents, attorneys, representatives,
shareholders and partners of each of the foregoing, and other persons acting on their behalf.
II.

“SST State Fund” means an interest-bearing escrow account established pursuant to

the Escrow Agreement, administered by the Escrow Agent and funded and distributed as set forth
in the SST Settlement Agreement.
JJ.

“State Fund” means an interest-bearing escrow account established pursuant to the

Escrow Agreement, administered by the Escrow Agent and funded and distributed as set forth in the
Mylan Settlement Agreement
KK.

“State Liaison Counsel” or “Liaison Counsel for Plaintiff States” means the Attorney

General o f the State of Ohio.
LL.

“Stipulated Permanent Injunction” means the injunction entered into between the

Commission and the Settling Defendants in the action entitled Federal Trade Commission v. Mylan,
et al., approved by the Commission on November 29, 2000, in the form o f Attachment 4 to the
Mylan Settlement Agreement.
III. APPLICABILITY
This Final Judgment and Order shall apply to the Plaintiff States, the Commission, the
Settling Members of the Settlement Group, the Settling Defendants, and SST Settling Defendant.
IV. FINAL APPROVAL OF SETTLEMENTS AND
CERTIFICATION OF THE SETTLEMENT CLASS
A.

With respect to the claims set forth in the Plaintiff States’ Complaint, the Court

confirms its Preliminary Approval Order and finds under the circumstances o f these settlements that
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the prerequisites to a class action set forth in Federal Rules o f Civil Procedure 23(a) and (b) are
satisfied, that the questions o f law and fact common to the members o f the class predominate over
any questions affecting only individual members, and that a class action is superior to other available
methods for the fair and efficient adjudication o f the controversy.
Accordingly, for the purpose o f these settlements only, a class consisting of
all natural person consumers within Plaintiff States where such a class
action may be brought, not otherwise represented by the Plaintiff States as
parens patriae, who purchased generic lorazepam and/or clorazepate sold
in the United States from January 1, 1998 through December 31, 1999
(the “Class”) is hereby certified. The States within that Class are set forth in Section VI. below.
B.

The Court finds that the Notice was the best notice practicable under the

circumstances and constitutes due and sufficient notice.
C.

The terms of the Settlement Agreements are adjudged as fair, reasonable and adequate

and in the best interest of consumers in the Plaintiff States and the Settlement Group as a whole, and
satisfy the requirements of Federal Rule o f Civil Procedure 23(e), state parens patriae laws and/or
state equitable authority and due process.
D.

The Settlement Agreements are hereby approved, and the Parties are directed to

implement the settlements in accordance with their terms.
E.

The Consumer Distribution Plan and Government Compensation Plan are hereby

approved, and Plaintiffs are directed to cause the settlement funds to be distributed in accordance
with said plans.
F.

All members of the Settlement Group were afforded the opportunity to exclude

themselves from the Settlement Group. A list of those members of the Settlement Group who timely
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and properly requested exclusion is attached hereto as Exhibit A.
G.

All payments made by Mylan Pharmaceuticals, Inc. and SST Corporation pursuant

to the Settlement Agreements are not, and shall not, be considered the payment of a penalty or fine
under any state or federal laws, rules or regulations, or any other applicable statute or provision.
V. INJUNCTION
The terms of the Stipulated Permanent Injunction entered into by Settling Defendants and
the Commission, which was approved by the Commission on November 29, 2000, shall be binding
on all the parties to the Mylan Settlement Agreement, and may be enforced by the Plaintiff States
for the term provided for in the Stipulated Permanent Injunction in the following manner:
A.

Settling Defendants shall provide the notices and/or reports pursuant to Sections VI,

VII and VIII o f the Stipulated Permanent Injuction to State Liaison Counsel, c/o Chief, Antitrust
Section, Office o f the Ohio Attorney General, 140 East Town Street, 12th Floor, Columbus, Ohio
43215.
B.

Communications

involving the Stipulated Permanent Injunction shall be

communicated to Settling Defendants by State Liaison Counsel. All such communications shall be
addressed to Settling Defendants as provided for in Secion XI(G) o f the Mylan Settlement
Agreement.
C.

Each Plaintiff State shall enforce Sections III, IV and V o f the Stipulated Permanent

Injunction through a committee comprised o f the Offices o f the Attorneys General for the States of
Ohio, Maryland and Kentucky (the “Committee”).
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D.

The Stipulated Permanent Injunction shall be enforced by the Plaintiff States by and

through the Committee in the District Court for the District o f Columbia.
VI. DISMISSAL OF ACTIONS AND RELEASES OF CLAIMS
Subject to the provisions o f Section IX o f this Final Judgment and Order, the Commission’s
and the Plaintiff States’ Complaints are dismissed with prejudice. The Commission, Plaintiff States,
and Settling Members of the Settlement Group are barred from further prosecution o f the Released
Claims, and Settling Defendants and SST Settling Defendant are released and forever discharged
from liability for the Released Claims.
The States o f Alabama, Alaska, Arizona, California, Colorado, Delaware, District of
Columbia, Hawaii, Idaho, Illinois, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan,
Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico,
New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylyania, Rhode Island, South Dakota,
Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin have
authority to release, and are releasing, Settling Members of the Settlement Groups’ claims pursuant
to each Attorney General’s parens patriae authority under state law.
The States o f Alaska, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana,
Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Montana,
Nebraska, Nevada, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South
Carolina, South Dakota, Texas, Utah, Virginia, Wisconsin, and Wyoming further have authority to
release, and are releasing, Settling Members o f the Settlement Groups’ claims pursuant to each
Attorney General's authority under Rule 23 o f the Federal Rules o f Civil Procedure.
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The State o f Colorado has further authority to release, and is releasing, Settling Members of
the Settlement Groups’ claims pursuant to the Attorney General’s equitable authority under §6-4111 C.R.S (2000).
The State o f Maryland has authority to release, and is releasing, Settling Members o f the
Settlement Groups’ claims pursuant to the Attorney General’s equitable authority under Md. Com.
Law Code Ann. §11-209.
The State o f Washington has further authority to release, and is releasing, its claims for the
benefit o f Settling Members o f the Settlement Group pursuant to the Attorney General’s equitable
authority under R.C.W. §19.86.080.
The State o f Wyoming has further authority to release, and is releasing Settling Members of
the Settlement Groups’ claims pursuant to the Attorney General’s authority under Wyoming Statute
§40-12-106.
VII. FEES AND COSTS
The Court approves the funding of the Cost and Fee Account as set forth in the Mylan
Settlement Agreement in the amount o f $__________ , and the funding of the SST Cost and Fee
Account as set forth in the S ST Settlement Agreement in the amount of $ __

, and directs

the Escrow Agent to disburse the funds accordingly.
VIII. FINALITY OF JUDGMENT
The Court finds that this Final Judgment and Order adjudicates all the claims, rights and
liabilities o f the Parties, and is final and shall be immediately appealable. Neither this Final
Judgment and Order nor the Settlement Agreements shall constitute any evidence or admission of
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liability by any Settling Defendant or SST Settling Defendant, nor shall they be offered in evidence
or used for any other purpose in this or any other matter or proceeding other than as may be
necessary to consummate or enforce the Settlement Agreements or the terms o f this Final Judgment
and Order, or by any Settling Defendant or SST Settling Defendant in connection with any action
asserting Released Claims.
IX. RETENTION OF JURISDICTION
Without affecting the finality of this Order, the Court retains jurisdiction for the purposes of
enforcing the terms o f the Settlement Agreements and enabling any o f the Parties to this Final
Judgment and Order to apply to this Court at any time for such further orders and directions as may
be necessary and appropriate for the construction or carrying out o f this Final Judgment and Order
for the modification o f any of the provisions hereof, and for the enforcement o f compliance herewith.

Dated______________

___________________________
Honorable Thomas F. Hogan
United States District Judge
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ATTACHMENT 3
UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

THE FEDERAL TRADE COMMISSION,
Plaintiff,
v.
MYLAN LABORATORIES, INC.,
CAMBREX CORP.,
PROFARMACO S.R.L., and
GYMA LABORATORIES OF AMERICA, INC.,
Defendants.

THE STATE OF CONNECTICUT, et a l
Plaintiffs,
v.
MYLAN LABORATORIES, INC.,
CAMBREX CORP.,
PROFARMACO S.R.L.,
GYMA LABORATORIES OF AMERICA, INC.,
and SST CORP.,
Defendants.

)
)
)
)
)
) Civ. No. 1:98-CV-3114 (TFH)
)
)
)
)
)
)
)
.)
)
)
)
)
)
) Civ. No. L98-CV-3115 (TFH)
)
)
)
)
)
)
)
)

ORDER PRELIMINARILY APPROVING PROPOSED SETTLEMENTS
WHEREAS the States o f Alabama, Alaska, Arizona, Arkansas, California, Colorado,
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Louisiana,
Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New

Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma,
Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont,
Washington, West Virginia, Wisconsin, Wyoming and the Commonwealths o f Kentucky,
Massachusetts, Pennsylvania, and Virginia, through their Attorneys General, and the District of
Columbia, through its Corporation Counsel, individually and as authorized by law, in the State’s
sovereign capacity, on behalf of state agencies, in a statutory, equitable and/or common law capacity,
and as representative o f and/or as parens patriae on behalf o f all natural person citizens of such state
who have purchased either or both o f the Relevant Drugs during the Relevant Period, the Federal
Trade Commission, and Mylan Laboratories, Inc., Gyma Laboratories o f America, Inc., Profarmaco
S.r.l., and Cambrex Corp., by and through their counsel of record in this litigation, have entered into
settlement o f this litigation;
WHEREAS the terms of this settlement are set forth in the Settlement Agreement between
the Plaintiff States and Commission and the Settling Defendants (“Mylan Settlement Agreement”);
WHEREAS the Plaintiff States and SST Corp., by and through their counsel of record in this
litigation, have entered into settlement o f this litigation;
WHEREAS the terms o f this settlement are set forth in the Settlement Agreement between
the Plaintiff States and SST Corp. (“SST Settlement Agreement”);
WHEREAS these settlements will, subject to this Court’s final approval, fully and finally
compromise, settle and resolve the Released Claims subject to the terms and conditions set forth
in the Mylan and SST Settlement Agreements (’’the Settlement Agreements”);
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WHEREAS the parties to these Settlement Agreements (the “Parties”) have filed them with
the Court and requested that the Court grant preliminary and final approval o f these settlements
pursuant to Federal Rule of Civil Procedure 23(e), and state parens patriae and/or statutory and
equitable authority;
WHEREAS the Court has read and considered the Settlement Agreements, the proposed
Notice Plan, and the pleadings and documents submitted in connection with the Parties’ request for
preliminary approval o f the Settlement Agreements, and good cause appearing therefor;
IT IS HEREBY ORDERED as follows:
PRELIMINARY APPROVAL OF SETTLEMENTS AND
CONDITIONAL CERTIFICATION OF THE SETTLEMENT CLASS
1.

This Court has jurisdiction over this action and each o f the Parties.

2.

The terms o f the Settlement Agreements are hereby preliminarily approved, subject to

further consideration thereof at the Settlement Hearing provided for below. The Court preliminarily
finds that the settlements encompassed by the Settlement Agreements (the “Settlements”), including
the proposed methods o f distribution and allocation o f the monies paid in settlement o f these actions
as outlined in the Consumer Distribution Plan and the Government Compensation Plan, are fair,
reasonable and adequate and in the best interest o f consumers in the Plaintiff States and the
Settlement Group as a whole, and their terms satisfy Federal Rule o f Civil Procedure 23(e), state
equitable and/or parens patriae laws, and due process so that notice of the Settlements should be
given as provided in this Order.
3.

For the purpose of these settlements only, a class consisting o f
All natural person consumers within Plaintiff
States where such a class action may be brought,
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not otherwise represented by the Plaintiff States
as parens patriae, who purchased generic
lorazepam and/or clorazepate sold in the United
States from January 1, 1998 through December
31,1999
(the “Class”) is hereby conditionally certified, pending final approval of the settlements herein.
4.

The Court preliminarily finds that:
(a)

The Attorneys General o f the States o f Alaska, California, Illinois, Kansas,

Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, North
Carolina, North Dakota, Ohio, Oregon, Rhode Island, South Dakota, Texas, Utah, Virginia and
Wisconsin, pursuant to their respective state’s parens patriae authority and Fed. R. Civ. P. 23, have
the authority to represent, settle and release the claims o f natural persons residing within their states.
(b)

The Attorneys General o f the States o f Alabama, Arizona, Colorado, Delaware,

Hawaii, Idaho, Maine, Missouri, New Hampshire, New Jersey, New Mexico, New York,
Pennsylvania, Tennessee, Vermont, Washington, West Virginia, and the District of Columbia,
pursuant their respective state’s parens patriae authority, have the authority to represent, settle and
release the claims o f natural persons residing within their states.
(c)

The Attorneys General of the States o f Arkansas, Connecticut, Florida, Georgia,

Indiana, Iowa, Nebraska, Oklahoma South Carolina, and Wyoming have the authority to represent,
settle and release the claims of natural persons residing within their states pursuant to Fed. R. Civ.
P. 23.
(d)

The Attorneys General o f the States o f Colorado and Maryland have the

authority to represent, settle and release the claims of natural persons residing within their states
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pursuant, to their equitable authority under §6-4-111C.R.S. (2000) and Md. Com. Law Code Ann.
§11-209, respectively.
(e)

The Attorney General of the State o f Washington has the further authority to

bring equitable claims for the benefit o f natural persons residing within her state, and to settle and
release such claims, pursuant to R.C.W. §19.86.080.
(f)

The Attorney General o f the State o f Wyoming has the further authority to

represent, settle and release the claims o f natural persons residing within the state under Wyoming
Statute §40-12-106.
NOTICE OF SETTLEMENT
5.

The Court finds that the form and content o f the proposed notice (the “Notice”),

attached as Appendix____ to Plaintiff States’ Memorandum in Support o f Motion for Preliminary
Approval o f Settlement Agreements, is in full compliance with the requirements o f Federal Rule of
Civil Procedure 23, state parens patriae laws, and state equitable authority and satisfies due process.
The Court further finds that the Notice provides to the Settlement Group sufficient information to
make an informed and meaningful decision regarding their options in this litigation and the effect
o f these settlements on their rights, and that the Notice Plan is the best practicable method o f notice
under the circumstances. The Court approves the Notice and the Notice Plan.
6.

The Court finds that the proposed_____ -day Notice Period is adequate. The Notice

Period shall run from _____ , 2001 until_______ ,2001.
7.

The Court confirms the Attorney General o f the State o f Ohio as Liaison Counsel for

the Plaintiff States.
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8.

As soon as practicable after entry o f this Order, but no later than ninety (90) days

after the date o f entry hereof, State Liaison Counsel shall cause notice to be disseminated to the
Settlement Group in accordance with the Notice Plan and the terms o f this Order.
REQUESTS FOR EXCLUSION
9.

All natural persons within the Settlement Group who submit valid and timely requests

for exclusion from the Settlement Group postmarked on or before________________ , 2001 pursuant
to instructions contained in the Notice, shall not have any rights under the Settlement Agreements
and shall not be bound by the Settlement Agreements or the Final Judgment and Order.
10.

All members o f the Settlement Group who do not submit valid and timely requests

for exclusion from the Settlement Group postmarked on or before_______________ , 2001 pursuant
to instructions contained in the Notice shall be bound by the Settlement Agreements and by the Final
Judgment and Order.
THE SETTLEMENT HEARING
11.

A hearing on final settlement approval (the “Settlement Hearing”) is hereby scheduled

to be held before the undersigned o n ________ _, 2001 at 10:00 a.m. in Courtroom No. 9, United
States Courthouse, 333 Constitution Avenue, N.W., Washington, D.C. 20001 to consider: (a) the
fairness, reasonableness and adequacy o f the Settlements, (b) the dismissal with prejudice of these
actions, and (c) the entry o f the Final Judgment and Order in these actions.
12.

Any member o f the Settlement Group who does not file a Request for Exclusion in

the manner set forth above may appear at the Settlement Hearing in person or by counsel and may
be heard, to the extent allowed by the Court, either in support o f or in opposition to the fairness,
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reasonableness and adequacy o f the Settlements and the dismissal with prejudice o f these actions as
to the Settling Defendants and SST Settling Defendant, and the entry of final judgment provided,
however, that no person shall be heard in opposition to the Settlements, or dismissal and/or entry of
final judgment, and no papers or briefs submitted by or on behalf of any such person shall be
accepted or considered by the Court, unless on or before_______ , 2001 such person: (a) files with
the Clerk of the Court a notice of such person’s intention to appear (“Notice o f Appearance”), as well
as a statement that indicates the basis for such person’s opposition to the Settlements, or the
dismissal o f claims and/or the entry of final judgment (“Statement”), and any documentation in
support o f such opposition, and (b) serves copies o f such Notice o f Appearance, Statement and
documentation, as well as any other papers or briefs that such person files with the Court, either in
person or by mail, upon the Mylan Antitrust Litigation Administrator, at P.O. B ox_____, Faribault,
Minnesota, and upon the following counsel:
Mitchell L.Gentile, Esq.
Office o f the Attorney General
140 East Town Street, 12th Floor
Columbus, OH 43215

James B. Weidner, Esq.
Clifford Chance Rogers
& Wells LLP
200 Park Avenue
New York, NY 10166

Richard Feinstein, Esq.
Federal Trade Commission
601 Pennsylvania Avenue, NW
Washington, DC 20580

13.

Sidney S. Rosdeitcher, Esq.
Paul Weiss Rifkind Wharton &
Garrison
1285 Avenue o f the Americas
New York, NY 10019-6064

The date and time of the Settlement Hearing shall be set forth in the Notices, but

shall be subject to adjournment by the Court without further notice other than that which may be
posted at the Court and on the Court’s web site.
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14.

All discovery and other pretrial proceedings in these actions were stayed and

suspended as o f August 4, 2000, pending the Effective Date o f the Settlements as defined in the
Settlement Agreements (“Final Approval”), and such stay continues, except such proceedings as are
provided for in the Settlement Agreements, or which may be necessary to implement the terms of
the Settlement Agreements or this Order.
15.

The Parties shall file with the Court any pleadings or memoranda in support o f the

Settlements and Settlement Agreements, including a statement that the Plaintiff States have
effectuated the Notice Plan, no later th a n ____________2001.
16.

Any Settling Member of the Settlement Group may hire an attorney at his or her own

expense to appear in this action. Such attorney shall serve the Notice o f Appearance, Statement, and
any supporting documentation on the counsel set forth in paragraph 12 on or before

___________,

2001, and file it with the Court on or b efo re____________ 2001.
17.

Pending Final Approval, the Settling Members o f the Settlement Group, Plaintiff

States and the Commission, either directly, representatively, or in any other capacity, shall not
commence or prosecute against the Settling Defendants or SST Settling Defendant, any action or
proceeding in any court or tribunal asserting any o f the claims or causes o f action that are to be
released by the Settlement Agreements upon Final Approval; and, upon Final Approval, all members
o f the Settlement Group who have not timely and validly excluded themselves from the Settlements,
the Plaintiff States and the Commission ("Releasing Parties") shall be forever enjoined and barred
from asserting any of the claims or causes of action released by the Settlement Agreements, and any
such Releasing Party shall be deemed to have forever released any and all such claims and causes
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o f action as provided for in the Settlement Agreements.
OTHER PROVISIONS
18.

The Court, for purposes o f this Order, adopts the definitions set forth in the

Settlement Agreements, unless otherwise defined herein.
19.

In the event the Settlements are terminated in accordance with the provisions o f the

Settlement Agreements, the Settlements and all proceedings had in connection therewith shall be null
and void, except insofar as expressly provided to the contrary in the Settlement Agreements, and
without prejudice to the status quo ante rights of the Settling Defendants and SST Settling Defendant
and the Releasing Parties.
20.

All proceedings in these actions against the Settling Defendants and SST are hereby

stayed until such time as the Court renders a final decision regarding the approval o f the Settlements
and, if it approves the Settlements, enters the Final Judgment and Order as provided in the
Settlement Agreements.
21.

Neither this Order nor the Settlement Agreements shall constitute any evidence or

admission of liability by any Settling Defendant or SST Settling Defendant, nor shall they be offered
in evidence in this or any other proceeding except to consummate or enforce the Settlement
Agreements or the terms of this Order, or by any Settling Defendant or SST Settling Defendant in
connection with any action asserting Released Claims.
SO ORDERED th is ______ day o f __________________ 2001.

Honorable Thomas F. Hogan
United States District Judge
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ATTACHMENT A
UNITED STATES DISTRICT COURT
FO R THE DISTRICT OF COLUMBIA

FEDERAL TRADE COMMISSION
Plaintiff,

)
)
)
)

)
) 98-CV-3114 (TFH)
)
MYLAN LABORATORIES, INC.,
)
CAMBREX CORP.,
)
PROFARMACO S.R.L., and
)
GYMA LABORATORIES OF AMERICA, INC., )
)
Defendants.
)
v.

_________________________________________________)

JO IN T M OTION TO APPROVE PERMANENT INJUNCTION
The parties jointly request that the Court approve the attached Order and Stipulated
Permanent Injunction. It is part o f the overall settlement of these matters.
RESPECTFULLY SUBMITTED,
Clifford Chance Rogers & Wells LLP
200 Park Avenue
New York, NY 10166
Richard A. Feinstein (D.C. Bar #324848)
Assistant Director, Bureau o f Competition
Federal Trade Commission
601 Pennsylvania Ave., NW
Vs. .ishmjaon, D.C. 20580
(202) '.2 .-3688

BY:
i
R
rlnAr P
enm rp
B
&
James
B. Weidner,
Esquire
(212) 878-8000
Attorneys for Defendant Mylan Laboratories, Inc.

Ws*!, C >tshaW?c Manges LLP
767 Fifth Avenue
New York, NY 10153

Debevoise & Plimpton.
875 Third Avenue
New York, NY 10022

;

by:

(212) 310 8000
Attorneys for Defendant Gyma Laboratories
Dated: November 29, 2000
Washington, DC

|¡j ÚtJfilr

ClriifoplxrItlL z Qy

Christopher TahRaz, Esquire
'
*
(212) 909-6543
Attorneys for Defendants Cambrex & Profarmaco

UNITED STATES DISTRICT CO U R T FOR THE
DISTRICT OF COLUMBIA

)
FEDERAL TRADE COMMISSION,

)
)

Plaintiff

)
)

Civil 1:98CV03114 (TFH)

v.

)
)
MYLAN LABORATORIES, INC.,
)
CAMBREX CORPORATION,
)
PROFARMACO S.R.L., and
)
GYMA LABORATORIES OF AMERICA, INC., )
)
Defendants
)
_________________________________________________ )

ORDER AND STIPULATED PERMANENT INJUNCTION
Whereas Plaintiff Federal Trade Commission ("Commission") has filed its amended
Complaint against Defendants Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco
4v.

S.r.l., and Gyma Laboratories of America, Inc., pursuant to Section 13(b) of the Federal Trade
Commission Act ("FTC Act"), 15 U.S.C. § 53(b), seeking injunctive and other equitable relief
for violations o f Section 5 o f the FTC Act, 15 U.S.C. § 45; whereas the Commission and
Defendants have stipulated and agreed to entry by the Court, without further notice, of the
following findings and permanent injunction; whereas this Order is entered for settlement
purposes only and does not constitute any evidence against or an admission o f liability yy the
Defendants; and whereas the Court, being advised in the premises, finds:
1.

The Commission brings this action under Sections 5 and 13(b) of the FTC Act,
15 U.S.C. §§ 45 and 53(b). In its Amended Complaint (dated February 8, 1999), the

1

Commission seeks permanent injunctive and other equitable relief, including
disgorgement. The Commission alleges that the Defendants conspired to monopolize and
entered into agreements that unreasonably restrained trade in the lorazepam and
clorazepate tablet and active pharmaceutical ingredient markets. The Commission further
alleges that Mylan Laboratories, Inc., monopolized and attempted to monopolize the
markets for lorazepam and clorazepate tablets. This Court has held that, pursuant to
Section 13(b), the Commission has authority to seek the relief it has requested.
2.

This Court has jurisdiction over the parties and the subject matter o f this action. Venue is
proper in the District o f the District o f Columbia. This Court has held that the Complaint
states a claim upon which relief may be granted against Defendants under Sections 5 and
13(b) o f the FTC Act, 15 U.S.C. §§ 45, 53(b).

3.

The Defendants' activities are in or affecting commerce, as defined in 15 U.S.C. § 44.

4.

This Court has held that this case is a proper case for the issuance o f a permanent
injunction pursuant to Section 13(b) o f the FTC Act, 15 U.S.C. § 53(b).

5.

Defendants waive all rights to appeal or otherwise challenge or contest the validity of this
Final Order and Stipulated Permanent Injunction, and Defendants waive any claim under
the Equal Access to Justice Act, 28 U.S.C. § 2412.

6.

Each Defendant, without admitting that it has violated Section 5 of the FTC Act, 15
a

U.S.C. § 45, or that entering an injunction under Section 13(b) o f the FTC Act, 15 U.S.C.
§ 53(b), is proper, agrees to the entry of this Order under Section 13(b) of the FTC Act,
15 U.S.C. § 53(b).
7.

Entry of this order is in the public interest.

2

I.

IT IS ORDERED that, as used in this Order, the following definitions shall apply:
A.

"Agreement" means anything that would constitute an agreement under Section 1 of the
Sherman Act, 15 U.S.C. § 1, or Section 5 of the Federal Trade Commission Act,
15 U.S.C. § 45.

B.

"ANDA" means Abbreviated New Thug Application, as defined under 21 U.S.C. § 355(j)
et seq.

C.

"API" means active pharmaceutical ingredient.

D.

"Cambrex" means Cambrex Corporation; its divisions and subsidiaries; and their
directors, officers, employees, agents, representatives, successors and assigns, and all
other persons or entities in active concert or participation with them, who receive actual
notice o f this Order by personal service or otherwise.

E.

"Commerce" has the same definition as it has in 15 U.S.C. § 44.

F.

"Commission" means the Federal Trade Commission.

G.

"DMF" means Drug Master File, as provided under 21 C.F.R. 314.420.

H.

"Enter into" means join, participate in, or implement.

I.

"FDA" means the United States Food and Drug Administration.

J.

"Gyma" means Gyma Laboratories of America; its divisions and subsidiaries; and their
directors, officers, employees, agents, representatives, successors and assigns, and all
other persons or entities in active concert or participation with them, who receive actual
notice of this Order by personal service or otherwise.
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K.

"Mylan" means Mylan Laboratories, Inc.; its divisions and subsidiaries, including Mylan
Pharmaceuticals; and their directors, officers, employees, agents, representatives,
successors and assigns, and all other persons or entities in active concert or participation
with them, who receive actual notice o f this Order by personal service or otherwise.

L.

"Person" means any natural person, partnership, corporation, or business entity.

M.

"Profarmaco" means Profarmaco S.r.l.; its divisions and subsidiaries; and their directors,
officers, employees, agents, representatives, successors and assigns, and all other persons
or entities in active concert or participation with them, who receive actual notice o f this
Order by personal service or otherwise.

N.

"Settlement Agreement" means the agreement (and attachments thereto) executed by the
Commission, the Plaintiff States, and Defendants, which governs the resolution o f the
above-captioned matter and the States Action.
II.
4&.

IT IS FURTHER ORDERED that, not later than three (3) days after service o f this
Order, Mylan Pharmaceuticals, Inc., pay $71,782,017 to an escrow fund forpurposes of
satisfying consumer claims in the related matter Connecticut v. Mylan, Civil 1:98CV03115
(D.D.C.) (the States Action), and $28,217,983 to an escrow fund for purposes of satisfying state
agency claims in the States Action. The escrow funds are intended to be qualified settlement
funds within the meaning of Treas. Reg. Sections 1.468B-1, et seq., and dhtril

ions from the

escrow funds are subject to the Settlement Agreement and further order from this Court.
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III.
IT IS FURTHER ORDERED that Defendants Mylan, Cambrex, Profarmaco, and Gyma
are each enjoined from entering into or attempting to enter into any agreement with any person,
in or affecting commerce, concerning any API if the agreement (1) prohibits the API supplier
from supplying any person not a party to the agreement, (2) prohibits any person not a party to
the agreement from referencing the API supplier's DMF, or (3) exclusively licenses the API
supplier's DMF; and further provided that the effect of such an agreement is to unreasonably
restrain trade, create an unlawful monopoly, or attempt to create an unlawful monopoly.

IV.
IT IS FURTHER ORDERED that Defendant Mylan is enjoined for five (5) years from
the date this Order is entered from entering into or attempting to enter into any agreement, in or
affecting commerce, with Defendants Cambrex, Profarmaco, or Gyma that (1) prohibits
t
Profarmaco, Cambrex, or Gyma from selling lorazepam or clorazepate API to any person,
(2) prohibits any person from referencing Profarmaco's DMF for lorazepam or clorazepate API,
or (3) exclusively licenses Profarmaco's lorazepam or clorazepate DMF to Mylan.
V.
IT IS FURTHER ORDERED that Defendant Mylan is enjoined from entering into or
attempting to enter into any agreement with any person, in or affecting commerce, concerning
any API, if (a) Mylan does not reference the API supplier’s DMF and (b) the agreement
(1) prohibits the API supplier from supplying any person not a party to the agreement,
(2) prohibits any person not a party to the agreement from referencing the API supplier's DMF, or
(3) exclusively licenses the API supplier's DMF.

5

VI.
IT IS FU R TH ER O RD ERED that, for five (5) years from the date this Order is entered,
Mylan shall notify the Commission thirty (30) days before entering into any agreement, in or
affecting commerce, with any person concerning any API for which the API supplier has a DMF,
if the agreement (1) prohibits the API supplier from selling the API to any person not a party to
the agreement, (2) prohibits any person not a party to the agreement from referencing the API
supplier's DMF, or (3) exclusively licenses the API supplier's DMF to Mylan. Such notice shall
include:
(a)

A copy o f the proposed agreement;

(b)

To the extent not reflected therein, the identification of all parties to such
agreement, the API(s) involved, and all terms relating to exclusivity and
compensation (including prices, profit-sharing, royalties, and other payments);
f

and
(c)

For the three most recent years, all IMS data, purchased in the ordinary course o f
business, relating to the finished drug product involved in the agreement, or, if no
IMS data is available, any available data on sales in units, prescriptions, and
dollars o f the finished drug product involved.

VII.

IT IS FU R TH ER ORDERED that, for five (5) years from the date this Order is entered,
Cambrex, Profarmaco or Gyma shall notify the Commission thirty (30) days before entering into
any agreement, in or affecting commerce, with any person concerning any API for which the API
supplier has a DMF, if the agreement (1) prohibits the API supplier from selling the API to any
6

person who references the DMF, (2) prohibits any person not a party to the agreement from
referencing the API supplier's DMF, or (3) exclusively licenses the API supplier's DMF. Such
notice shall include:
(a)

A copy o f the proposed agreement;

(b)

To the extent not reflected therein, the identification of all parties to such
agreement, the API(s) involved, and all terms relating to exclusivity and
compensation (including prices, profit-sharing, royalties, and other payments);
and

(c)

Data sufficient to show each sale of the API involved in the agreement in the past
three years, the identity and location o f the customer for each sale, the amount in
kilograms o f each sale, and the total amount in dollars of each sale o f the API
involved.
VIII.

IT IS FURTHER ORDERED that each Defendant shall:
A.

File a verified, written report with the Commission setting forth in detail the
manner and form in which it has complied and is complying with this Order:
(1) within ninety (90) days from the date this Order is entered, (2) annually
^thereafter for five (5) years on the anniversary of the date this Order is entered,
and (3) at such other times as the Commission may require by written notice.

B.

For a period of five (5) years from the date this Order is entered, maintain and
make available to Commission staff for inspection and copying upon reasonable
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notice, records sufficient to describe in detail any action taken in connection with
the activities covered by this Order.
C.

Notify the Commission at least thirty (30) days prior to (1) any proposed change
in the corporate Defendant, such as its dissolution, assignment, or sale resulting in
the emergence o f a successor corporation, or (2) any other change or the creation or dissolution o f subsidiaries that may affect compliance obligations arising out of
this Order.

D.

Address each notice and report that this Order requires to Federal Trade
Commission, Office of the Secretary, 600 Pennsylvania Avenue, NW,
Washington, DC 20580, and send a copy of each notice pursuant to paragraphs VI
and VII to the Assistant Director o f Health Care, Bureau of Competition, at the
same address.
IX.

IT IS FU R TH ER ORDERED that the following do not violate, and are not subject to,
the Order:
A.

Any agreement relating to:
(1)

Any API or finished drug product during the period the manufacture and
sale of which is protected by a patent.

■»

(2)

_

The development o f any patentable API or finished drug product for which
a New Drug Application would be necessary to sell the finished drug
product in the United States.

(3)

The development of any API or generic finished drug product, if the API
supplier has not filed a DMF with the FDA at the time of the agreement.
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(4)

The development of any generic finished drug product, if there is no
existing or pre-existing commercially available generic finished drug
product that references the API supplier’s DMF at the time o f the
agreement.

B.

Any exclusive distributorship agreement, such as that currently in effect between
Profarmaco and Gyma, by which the API supplier designates an exclusive
distributor of one or more APIs to API purchasers in the United States or any
portion thereof.

C.

Any purchase order for any API submitted to, and accepted by, an API supplier in
the ordinary course o f business.
X.

IT IS FURTHER ORDERED that this Order shall take effect on, and expire ten (10) years
t

from, the date this Order i | entered, and that this Order may become null and void before the
expiration o f the ten-year period as provided in the Settlement Agreement or by further order of the
Court.
XL
IT IS FURTHER ORDERED that the Court retains jurisdiction of this matter for purposes
o f construction, modification and enforcement of this <Tier.

Washington, DC, this

day o f

2000.

Thomas F. Hogan
UNITED STATES DISTRICT JUDGE
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ATTACHMENT 5
GUIDELINES GOVERNING PAYMENT OF
ATTORNEYS’ FEES AND LITIGATION COSTS
The Escrow Agent shall disburse the Cost and Fee Account, exclusive o f any interest
earned thereon, to the Attorneys General representing the Litigating Plaintiff States as payment
for their attorneys’ fees and costs incurred in investigating, litigating and settling this action.
Such costs shall include reimbursement o f the National Association of Attorneys General Milk
Fund Account (“NAAG Milk Fund”) for consultant and expert fees expended from the NAAG
Milk Fund by the Litigating Plaintiff States. After reimbursement is made to the NAAG Milk
Fund, the remaining portion o f the Cost and Fee Account shall be apportioned among the
Litigating Plaintiff States in their sole discretion and such apportionments shall then be used by
the Litigating Plaintiff States’ Attorneys General for one or more of the following purposes, as
determined by the Attorney General of each Litigating Plaintiff State, at his or her exclusive
option, and as otherwise consistent with the laws o f his or her respective state:1
(1) .
Reimbursement of Litigating Plaintiff States’ attorneys’ fees and/or investigation,
litigation and settlement administration costs incurred by such state;
(2) .
Reimbursement o f Litigating Plaintiff States’ consultants’ and experts’ fees and
costs incurred by such state;
(3) . Antitrust or consumer protection enforcement by the Attorney General o f such
state;
(4) . Deposit into a state antitrust or consumer protection account (e.g., revolving
‘With respect to the State o f Colorado, its apportionment shall be used first for
reimbursement o f Colorado’s actual costs and attorneys fees and second, to be held, along with
any interest thereon, in trust by the Attorney General for future consumer education, consumer
fraud or antitrust enforcement efforts. With respect to the State o f Maine, its apportionment shall
be used for enforcement of the Maine Unfair Trade Practices Act, pursuant to 5 M.R.S.A. §209.
]

account, trust account) for use in accordance with the state laws governing that account;
(5).
Deposit into a fund exclusively dedicated to assisting the State Attorney General
to defray the cost o f experts, economists, and consultants in multistate antitrust
investigations and litigations.
The Escrow Agent may pay all interest accrued on the Cost and Fee Account, up to a
maximum of $200,000, into the NAAG Milk Fund to partially reimburse the Fund for past
unreimbursed expenditures from the Fund. The Court’s consideration of cost and fees shall be
separate from the Court’s consideration of the fairness, reasonableness and adequacy of the
remaining terms o f this Settlement Agreement. The Plaintiff States hereby explicitly agree that
in the event the Court adopts a plan for payment o f fees and costs other than that contained
herein, the Plaintiff States will not object to or oppose approval o f the remainder o f the
Settlement Agreement by the Court, or otherwise delay or affect approval o f the settlement, or
entry o f the Final Judgment and Order.
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ATTACHMENT 6
GUIDELINES GOVERNING DEVELOPMENT OF
GOVERNMENT COMPENSATION PLAN
The Escrow Agent shall distribute all funds remaining in the Agency Account o f the State
Fund after payment of the costs set forth in subsection V I.A .l. o f the Settlement Agreement,
according to the Government Compensation Plan. In the event a state or states do not opt into
this Settlement Agreement pursuant to the terms o f Section IX.B o f the Settlement Agreement,
the Government Compensation Plan shall be amended to distribute such state’s share of the
Agency Account among the Plaintiff States based on estimates o f actual damages. Each Plaintiff
State, through its Attorney General or as otherwise authorized by state law, shall be responsible
for determining how to allocate its portion of the Agency Account. The Plaintiff States shall
submit the Government Compensation Plan to the Court with the motion for Preliminary
Approval of the settlement.
4b.

The Parties agree and understand that the Government Compensation Plan is not a part of
the Settlement Agreement and the Court’s consideration o f the fairness o f the Government
Compensation Plan is to be considered separately from the Court’s consideration o f the fairness,
reasonableness and adequacy o f the settlement set forth in the Settlement Agreement. Any order
or proceedings relating to the Government Compensation Plan shall not operate to terminate or
cancel the Settlement Agreement or affect the finality o f the Court’s judgment approving the
Settlement Agreement, the Final Judgment and Order, or any other orders entered pursuant to the
Settlement Agreement.
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ATTACHMENT 7
GUIDELINES GOVERNING DEVELOPMENT
OF CONSUMER DISTRIBUTION PLAN
The Escrow Agent shall distribute and/or administer the distribution o f all funds
remaining in the Consumer Fund after payment o f the costs and expenses set forth in Section
VI.A.2 of the Settlement Agreement, according to the Court-approved Consumer Distribution Plan.
The following provisions shall govern the Consumer Distribution Plan.

The Consumer

Distribution Plan shall provide for distribution of that portion o f the Consumer Fund that remains
unclaimed following direct payment o f consumer claims. Such remainder shall be allocated to the
Litigating Plaintiff States for cy pres distribution. The following provision applies to any cy pres
distribution o f settlement proceeds:

Each Litigating Plaintiff State, through its Attorney General or as otherwise authorized by
state law, shall direct that its share of the unclaimed remainder o f the Consumer Fund be
distributed to that State, a political subdivision(s) thereof, and/or a charitable organization(s)
qualified as an exempt organization under §501(c)(3) o f the Internal Revenue Code, with
express conditions and in accordance with the Court-approved Consumer Distribution Plan
ensuring that the funds be used in a manner reasonably targeted to specifically benefit the
health care needs o f a substantial number of the persons injured by the increased prices of
the Relevant Drugs during the Relevant Period. A Litigating Plaintiff State choosing to
directly receive its share o f the unclaimed remainder o f the Consumer Fund may directly
appropriate such funds, subject to the above-stated conditions, or may distribute such funds
to a political subdivision(s) thereof, and/or a charitable organization(s) qualified as an
exempt organization under §501(c)(3)ofthe Internal Revenue Code to be used subject to the
express conditions stated above.
The Plaintiff States shall submit their proposed Consumer Distribution Plan, together
with a proposed Notice Plan, to the Court for approval with the motion for preliminary approval
o f the settlement. Litigating Plaintiff States shall submit their proposals for cy pres distribution
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o f the unclaimed remainder o f the Consumer Fund to the Court for approval with their motion
for final approval o f the settlement.
The Parties agree and understand that the v^onsumer Distribution Plan is not a part o f the
Settlement Agreement and the Court’s consideration o f the fairness o f the Consumer Distribution
Plan is to be considered separately from the Court’s consideration o f the fairness, reasonableness
and adequacy o f the settlement set forth in the Settlement Agreement. Any order or proceedings
relating to the Consumer Distribution Plan shall not operate to terminate or cancel the Settlement
Agreement or affect the finality o f the Court’s judgment approving the Settlement Agreement,
the Final Judgment and Order, or any other orders entered pursuant to the Settlement Agreement.
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